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ABSTRACT 
TITLE OF THE THESIS:  
Drug emergent metabolic syndrome in patients on antipsychotic medication 
DEPARTMENT                          :          Psychiatry 
NAME OF THE CANDIDATE:          Akhil Abhijnhan 
DEGREE AND SUBJECT         :          MD Psychiatry 
NAME OF THE GUIDE            :          Dr. Deepa Ramaswamy 
OBJECTIVES (30 WORDS):  
This study aims to estimate the prevalence and incidence of metabolic syndrome in 
antipsychotic naive psychiatric population followed up over 3 months and to identify 
associated risk factors. 
METHODS (100 WORDS): 
A prospective cohort study was conducted where the prevalence of metabolic syndrome in 
antipsychotic naive patients was measured at the time of recruitment. Those who did not 
fulfil the criteria for metabolic syndrome and required antipsychotic medications were 
followed up over a period of 3 months and reassessed for the incidence of metabolic 
syndrome. Participants fulfilling the inclusion and exclusion criteria were recruited from both 
outpatient and inpatient facilities in the department of Psychiatry, Christian Medical College- 
Vellore. Socio-demographic, anthropometric, blood pressure and blood parameters were 
recorded in addition to making note of other risk factors such as family history. 
RESULTS (90 WORDS):  
Analysis of baseline characteristics was done using 148 participants. Prevalence of metabolic 
syndrome in antipsychotic naive patients with mental illness was 19% using National 
Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) definition while it 
was 12% with International Diabetes Federation (IDF) criteria. Prevalence of sub-threshold 
metabolic syndrome was 40% when only 2 criteria and 74% when any one of the NCEP ATP 
III criteria were fulfilled. Three months later, analysis of the full data available for 14 
participants gave incidence rate of 7% using NCEP ATP III definition. 
 
KEYWORDS: metabolic syndrome, antipsychotic naive, NCEP ATP III, IDF 
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INTRODUCTION 
 
Metabolic syndrome is the term used to define a group of risk factors, which when 
clustered in an individual, increases the risk for subsequent development of coronary 
artery disease, type 2 diabetes mellitus and stroke. The metabolic syndrome comprises 
of central obesity, elevated cholesterol and triglycerides, impaired glucose tolerance 
and increased blood pressure. The overall risk for morbidity and mortality increases 
with the presence of metabolic syndrome in an individual. 
People with chronic and severe mental illnesses like schizophrenia are prone to 
develop the metabolic syndrome.  This propensity can be attributed to illness related 
factors modifying their lifestyles, genetic predisposition and due to the use of 
antipsychotic medications. There has been immense interest among the academic and 
routine clinical circles about the role of antipsychotic medications in the pathogenesis 
of the metabolic syndrome. This has been of particular interest given the current 
clinical practice guidelines of a shift in the use of second generation antipsychotic 
medications as first line choice in psychiatric illness. 
Numerous risk factors have been implicated in the development of metabolic 
syndrome. These include genetic vulnerability, lifestyle factors, poor diet habits, use 
of nicotine and alcohol, diabetes and chronic illnesses. The prevalence of metabolic 
syndrome is clearly high in people who have first degree relatives suffering from 
diabetes mellitus or dyslipidemia.  
 
 
14 
 
Prevention is one of the major armaments in the management of the metabolic 
syndrome as it ameliorates the risk of complications such as diabetes mellitus or 
cardiovascular events. The major preventive measures advocated are of weight 
reduction and regular physical exercise. Pharmacological interventions are 
recommended only when the above mentioned strategies fail. Overall 
pharmacological interventions have not been found to play a significant role in the 
management of metabolic syndrome. 
The metabolic syndrome currently affects about a quarter of the world population. 
Distinct patterns in the prevalence of this syndrome have been identified with respect 
to high risk regions and ethnicities.  Studies have also shown that there is a higher risk 
of metabolic syndrome in psychiatric populations on antipsychotic medications.  
In this study we set out to identify antipsychotic naive patients who required 
treatment, evaluated their metabolic status, and followed them up over a period of 
three months to evaluate the development of metabolic syndrome. We also aimed to 
look at the possible factors which possibly influence or predict the development of 
metabolic syndrome is this specific subset of patients. 
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REVIEW OF LITERATURE 
Metabolic Syndrome 
Metabolic Syndrome signifies a collection of signs and symptoms, the presence of 
which is hypothesized to increase the risk of subsequent development of diabetes 
mellitus, stroke or coronary artery disease. On a broad perspective the major traits that 
are screened for are the presence of central obesity, dyslipidemia, impaired glucose 
tolerance and elevated blood pressure. As this syndrome has the propensity to 
increase an individual’s risk of metabolic and coronary complications, it contributes 
significantly to the overall morbidity and mortality rates. 
The historical roots to the origin of this syndrome can be traced back to the Italian 
physician and anatomist Morgnani who identified the association between episodes of 
what is now known as obstructive sleep apnoea and the presence of visceral obesity, 
elevated serum uric acid levels, hypertension and atherosclerosis. This syndrome as a 
separate entity that we understand today has bearing on the evolution of the clinical 
concepts of obesity and insulin resistance. In the 1920’s various associations of risk 
factors for diabetes mellitus were hypothesised. A significant development in the 
1940’s was Harvard psychologist William Sheldon’s theory of different somatotypes 
(ectomorph, endomorph and mesomorph) predisposing towards different 
temperaments, which was based on the differences in the distribution of adipose tissue 
on different parts of the body(1).  In Marseilles in 1947, Dr Jean Vague made 
observations that upper body obesity (android obesity) predisposes to the 
development of atherosclerosis, calculi, diabetes and gout(2). According to him these 
findings were in stark contrast to the pattern of obesity he observed in women (gynoid 
obesity).  Since he observed that these patterns were not exclusively limited to each 
gender, he even developed a formula called the “Index of Masculine Differentiation” 
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to quantitatively express the pattern. This was followed up in the 1960’s by Avogaro 
and colleagues who made observations of frequent clustering of obesity, increased 
blood fat, diabetes mellitus and hypertension, and subsequent risk of coronary artery 
disease(3). The term “metabolic syndrome” was first used by Haller in 1977 when 
describing the additive effects of risk factors such as associations of diabetes mellitus, 
hepatic steatosis, hyperlipoproteinemia, hyperuricemia and obesity with 
atherosclerosis. In the same year Singer and colleagues used the same term for the 
association of cluster of obesity, gout, diabetes mellitus and hypertension with 
hyperlipoproteinemia.  
This was however followed by a period of confusion in the 1980’s when Jean Vague 
stated that visceral fat mass did not by itself contribute to the development of diabetes 
mellitus. A shift in the focus from obesity to the concept of insulin resistance was 
evident by the late 1980’s and was highlighted by the seminal work of Gerald Reaven, 
who in his Banting Lecture to the American Diabetes Association in 1988 used the 
name Syndrome X to enumerate risk factors for the pathogenesis of coronary artery 
disease(4). These included disturbances of glucose and insulin metabolism, obesity, 
dyslipidaemia and hypertension. Reaven hypothesised that insensitivity to insulin 
leads to elevated levels of insulin in the blood which was the major aetiopathological 
mechanism. Ferranini and colleagues supported this theory and coined the term 
Insulin resistance syndrome(5). Norman Kaplan introduced the term “deadly quartet” 
to the occurrence of glucose intolerance, hypertension, hypertriglyceridemia and 
upper –body obesity wherein he melodramatically assigned the pathogenic role to the 
presence of hyperinsulinemia (6). Metabolic syndrome is also known by the term 
“Syndrome X Plus”. This was an amalgamation of the elements of syndrome X 
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described by Reaven to additional elements of  upper body obesity, physical inactivity 
and ageing(7).  
PATHOPHYSIOLOGY 
The current understanding is that of complex interactions between genetic and 
environmental factors underpinning the aetio-pathogenesis of the Metabolic 
Syndrome. These factors can be summarised: 
Insulin resistance & Glucose intolerance 
Central Obesity 
Hypertension 
Dyslipidaemia 
Pro-inflammatory state 
Prothrombotic state 
Genetics 
Insulin resistance & Glucose intolerance 
Insulin resistance has been postulated to be one of the primary pathogenic 
mechanisms(8). Insulin is secreted by the pancreas. It’s major function is as an 
anabolic hormone influencing the metabolism of proteins and lipids; transport of 
amino acid and ions, and inadvertently  affecting the cell cycle (9). In Insulin 
resistance the target organs lose the ability to utilize insulin leading to increased 
insulin level in the blood.(10). The hyperinsulinemia compensates by maintaining 
normoglycemia but causes insulin hyperactivity in other target organs which is 
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hypothesised to lead to the development of metabolic syndrome(11). Insulin 
resistance has been postulated to be the result of defects at various sites including the 
receptor itself, the pre-receptor and post receptor. The anti-atherogenic property of 
insulin is affected in insulin resistance through phosphatidlyinositol-3kinase pathway 
impairment(9). 
Abdominal adipose tissue deposits have been believed to have a central role in the 
development of insulin resistance. These abdominal stores are known to release non-
esterified fatty acids into the blood through which they get over deposited in the liver 
and muscle. This leads to over activity of insulin and subsequent development of 
insulin resistance in these tissues. The insulin over activity leads to lipolysis in the 
fatty tissues through its stimulatory effect on lipoprotein lipase. As a result the level 
of free fatty acids increases. These free fatty acids produce toxic substances which 
further increase the insulin resistance, hence leading to a vicious cycle (12). Of all the 
fat stores, visceral fat is considered to be most detrimental(11). Hyper insulinemia 
also accelerates the production of very low density lipoproteins and thereby 
increasing the triglyceride levels and resultant hypertension(13). 
Central Obesity 
The role of central obesity in metabolic syndrome is evident from the stance taken by 
the IDF to use “central obesity syndrome” as a synonym(14).  The central fat stores 
are considered to be more metabolically active that the peripheral reserves. Studies 
have proposed that the development of central obesity precedes that of other 
components of the metabolic syndrome and have emphasised weight reduction as the 
primary prevention strategy(15).  Central obesity has also been incriminated in 
hypothesis related to development of lipotoxicity. The metabolic products released by 
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the visceral fat stores gain direct entry to the liver through the portal circulation. Thus 
free fatty acids accumulate in the liver, pancreas and the heart leading the respective 
organ dysfunctions. This has the cumulative effect of impaired regulation of blood 
cholesterol and insulin levels. 
So based on the current understanding there can be two hypotheses: 
1. Common Soil Theory: metabolic syndrome and central obesity are not 
causally linked but are common endpoints to shared genetic and 
environmental factors. 
2. The visceral adipocytes are more metabolically active than their peripheral 
counterparts and hence enhanced lipolysis contributes towards elevated levels 
of free fatty acids in the plasma. 
The metabolic products of the visceral adipocytes drain directly into the liver due to 
the anatomical advantage via the portal venous system (16)(17) 
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Pathophysiology of  Central Obesity as cause for metabolic syndrome(17) 
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Hypertension 
Hypertension is one of the key symptoms of the metabolic syndrome.  All the 
components of the metabolic syndrome are hypothesized to influence the 
pathogenesis of hypertension. This is one of the elements of the metabolic syndrome 
which has a high tendency to go undetected. Hypertension has been most commonly 
associated with dyslipidaemia, glucose intolerance and obesity(18). Some authorities 
suppose that out of these factors, obesity maybe the strongest risk factor for 
uncontrolled hypertension. The Framingham Heart Study  results highlighted that in 
78% of men and 65% of women, excess weight was contributory towards developing 
hypertension(19). Insulin and leptin are two hormones which have been postulated to 
be further evidence of the strong correlation between obesity and hypertension. (20). 
Leptin is proposed to increase the blood pressure by sympathetic nervous system 
activation(21) 
Another mechanism in the pathogenesis of hypertension is the activation of the Renin-
Angiotensin System (RAS) by hyperglycemia and insulin with resultant elevation of 
Angiotensin, AT1 receptor and Angiotensin II in the context of insulin resistance (22) 
Dyslipidaemia 
In the metabolic syndrome, the major changes seen in the lipid profile are increase in 
triglyceride levels and a fall in the high density lipoprotein (HDL) cholesterol levels.  
As a result of insulin resistance the serum levels of insulin will be elevated. This 
would theoretically lead to the breakdown of free fatty acids into triglycerides. 
Obesity is also associated with low levels of HDL. Elevated levels of triglycerides 
also contribute to reduction in the HDL levels. The reduction is not only in the 
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number but also in the size of individual HDL particles. The smaller HDL particles 
are less efficient in combating the process of atherogenesis.  
The low density lipoproteins (LDL) generally maintain normal levels in the metabolic 
syndrome. They are however more denser and smaller which facilitate atherogenesis 
and increased risk of developing Ischemic Heart Disease (23). 
Pro-inflammatory state 
Metabolic syndrome has long been associated with chronic subclinical inflammation 
(12). More specifically insulin resistance and endothelial dysfunction have been found 
to be associated with low grade inflammation(24). It has also been hypothesised that 
the inflammatory cytokines released by adipose tissue lead to insulin resistance. 
Another model views metabolic syndrome and obesity as forms of stress which the 
body handles by activation of the inflammatory pathway. Proponents of this model 
have put forward the term “metaflammation” to signify metabolically triggered 
inflammation. Studies have shown positive association between obesity and C-
reactive protein in women (25) . These findings have prompted researchers to argue 
for the inclusion of CRP as a criterion to diagnose metabolic syndrome (26).  
Prothrombotic state 
Metabolic syndrome is characterised by elevated levels of plasma plasminogen 
activator inhibitor 1 (PAI-1) and fibrinogen. Like the CRP, fibrinogen is also an acute 
phase reactant.  Hence in the metabolic syndrome, both prothrombotic and and 
proinflammatory phases might be interconnected(13). Studies have shown elevated 
levels of Thrombin Activatable Fibrinolysis Inhibitor (TAFI), CRP, IL6 and 
fibrinogen in metabolic syndrome. These 4 biomarkers have been proposed to be 
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included among the risk assessment for metabolic syndrome(27), though they are not 
currently included in any of the diagnostic guidelines. 
Genetics 
Current low power studies and the difference of opinions on the definition of 
metabolic syndrome have not facilitated in the identification of any strong candidates 
to propose genetic causality.  Most of the proposed gene candidates are involved in 
energy storage functions and highlight the thrifty phenotype (28). It is hypothesized 
that when these genetic variants are exposed to an environment with high caloric diet 
in the absence of physical activity, they breakdown and form the phenotype with the 
dysfunction typical of the metabolic syndrome. Predominantly genes regulating 
thermogenesis and  lipolysis are the prime candidates (29). Others include those 
working on adrenergic b-receptors (ADRB1, ADRB2 and ADRB3); insulin receptor 
substrates (IRS), tumor necrosis factor- alpha etc. 
 
GENETIC FACTORS CONTRIBUTING TO METABOLIC SYNDROME(28) 
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Critique of Metabolic syndrome 
The existence of the metabolic syndrome as a separate entity was questioned by a 
joint statement put forward by the American Diabetes Association and the European 
Association for the Study of Diabetes(30). The arguments were directed towards the 
lack of clarity of definition, multiple different phenotypes within the syndrome, lack 
of evidence base for setting up cut offs for the various components, inclusion in 
certain definitions of people with cardiovascular disease or diabetes and the non-
inclusion of other risk factors (e.g. inflammatory markers) which may have equal or 
even greater contribution to the risk. The critical weakness of the current metabolic 
syndrome construct is that treatment of the syndrome is no different than treatment for 
each of its components. 
This critique has been countered with the argument that focusing on central obesity as 
the pathogenesis behind metabolic syndrome takes out of the equation “other 
contributing risk factors” which fail to make it into the criteria for metabolic 
syndrome(31). Regarding the utility of metabolic syndrome, it has been highlighted 
that for mental health practitioners it is a less cumbersome method of calculating risk 
as opposed to using the Framingham score (32). Its utility as a construct which 
enables to label patients and initiate intensive intervention before the complications 
set in has also been emphasised on (33). 
Definitions and Diagnosis 
In the absence of concrete theories on the aetio-pathogenesis of metabolic syndrome, 
there are numerous definitions used to diagnose this syndrome. Guidelines provided 
by the WHO (World Health Organization), IDF (International Diabetes Federation) 
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and the revised National Cholesterol Education Program are the most widely 
employed ones. Each guideline reflects the predominant aetio-pathological model 
adopted. 
World Health Organisation (WHO) 
The WHO consultation group in 1998 gave a definition for metabolic syndrome along 
with a provisional classification of diabetes. This report was finalised by the WHO the 
following year and was published in their website(34). The primary outcome was the 
development of cardiovascular disease. Insulin resistance was defined as a 
prerequisite to diagnose the syndrome. This guideline also provided a set of criteria to 
identify insulin resistance. In addition to insulin resistance two other risk factors were 
required to complete the diagnosis. 
Insulin resistance was defined as one of the following: 
1. Type 2 diabetes 
2. Impaired fasting glucose (IFG) 
3. Impaired glucose tolerance (IGT) 
4. Or for those with normal fasting glucose values (<110 mg/dL), a glucose 
uptake below the lowest quartile for background population under 
hyperinsulinemia, euglycemic conditions. 
Plus any 2 of the following: 
  • Antihypertensive medication and/or high blood pressure (≥140 mm Hg 
systolic or ≥90 mm Hg diastolic) 
  •  Plasma triglycerides ≥150 mg/dL (≥1.7 mmol/L) 
  • HDL cholesterol <35 mg/dL (<0.9 mmol/L) in men or <39 mg/dL (1.0 
mmol/L) in women 
  •  BMI >30 kg/m2 and/or waist:hip ratio >0.9 in men, >0.85 in women  
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  • Urinary albumin excretion rate ≥20 µg/min or albumin:creatinine ratio ≥30 
mg/g 
Derived from Alberti et al(34). 
One of the disadvantages of the WHO criteria is the need for special testing of blood 
glucose other than those used in routine clinical assessment. 
 
EGIR (European Group for the Study of Insulin Resistance) 
The European Group for the Study of Insulin Resistance in 1999 recognized the 
practical clinical difficulty in measuring insulin resistance in diabetic patients, while 
acknowledging that fasting insulin values were reliable measure of insulin resistance 
in non diabetic patients. The EGIR recommended that metabolic syndrome could be 
defined by the top 25% of the fasting insulin values among non-diabetic individuals  
AND two or more of the following: 
• Central obesity: waist circumference ≥ 94 cm (male), ≥ 80 cm (female) 
• Dyslipidemia: TG ≥ 2.0 mmol/L and/or HDL-C < 1.0 mmol/L or treated for 
dyslipidemia 
• Fasting plasma glucose ≥ 6.1 mmol/L 
• Hypertension: blood pressure ≥ 140/90 mmHg or antihypertensive medication 
National Cholesterol Education Program Adult Treatment Panel III  (NCEP-ATPIII) 
The NCEP-ATP III was introduced in 2001. The primary clinical outcome for the 
metabolic syndrome according to the NCEP-ATPIII was identified as cardiovascular 
disease.  Priority was placed on abdominal obesity. This was recognised by increase 
in the waist circumference which was listed as the first criterion. This clearly implied 
the emphasis laid on central obesity as the primary aetio-pathogenic factor in 
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metabolic syndrome. When 3 out of the 5 listed characteristics are present, a diagnosis 
of metabolic syndrome can be made: 
1.Abdominal obesity, given as waist circumference  
    Men >102 cm (>40 in) 
    Women >88 cm (>35 in) 
2.Triglycerides ≥150 mg/dL 
3.HDL cholesterol  
    Men <40 mg/dL 
    Women <50 mg/dL 
4.Blood pressure  ≥130/≥85 mm Hg 
5.Fasting glucose ≥110 mg/dL‡ 
 
After the publication of the NCEP ATP III, The American Diabetes Association 
established a new cut point of ≥100 mg/dL, above which persons have either 
prediabetes (impaired fasting glucose) or diabetes(35). This new cut point should be 
applicable for identifying the lower boundary to define an elevated glucose as one 
criterion for the metabolic syndrome. 
The main advantage with the NATIONAL CHOLESTEROL EDUCATION 
PROGRAM-ADULT TREATMENT PANEL III criteria is that it is more user 
friendly. Moreover this guideline gives criteria which can be equally utilized in both 
clinical and research settings. 
 
28 
 
International Diabetes Federation (IDF) 
The International Diabetes Federation introduced its diagnostic criteria in 2006. The 
primary clinical outcome targeted was both diabetes mellitus and cardiovascular 
disease. IDF places more importance on abdominal obesity in comparison to other 
components of metabolic syndrome. IDF introduced ethnic specific values for the 
measurement of waist circumference.  
According to the IDF a diagnosis of metabolic syndrome can be made if the patient 
has: 
1. Central obesity (defined as waist circumference# with ethnicity-specific 
values)  
• ≥ 94 cm in Europid men and ≥ 80 cm in Europid women 
• ≥ 90 cm in men and ≥ 80 cm in women from south and south east 
Asian, Japanese and ethnic south and central American origins 
2. AND any two of the following: 
• Raised triglycerides: > 150 mg/dL (1.7 mmol/L), or specific treatment for this 
lipid abnormality 
• Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in males, < 50 mg/dL 
(1.29 mmol/L) in females, or specific treatment for this lipid abnormality 
• Raised blood pressure (BP): systolic BP > 130 or diastolic BP >85 mm Hg, or 
treatment of previously diagnosed hypertension 
Raised fasting plasma glucose (FPG): >100 mg/dL (5.6 mmol/L), or 
previously diagnosed type 2 diabetesIf FPG is >5.6 mmol/L or 100 mg/dL, an 
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oral glucose tolerance test is strongly recommended, but is not necessary to 
define presence of the syndrome. 
#
 If BMI is >30 kg/m², central obesity can be assumed and waist circumference 
does not need to be measured 
American Association of Clinical Endocrinologists (AACE) 
The American Association of Clinical Endocrinologists proposed a third set of criteria 
for the diagnosis insulin resistance syndrome. 
RISK FACTOR COMPONENTS and CUT-POINTS FOR ABNORMALITY 
Overweight/obesity   BMI ≥25 kg/m2 
Elevated triglycerides ≥150 mg/dL (1.69 mmol/L) 
Low HDL 
cholesterol 
Men < 40 mg/dL (1.04 mmol/L) 
Women < 50 mg/dL (1.29 mmol/L) 
Elevated bloo pressure ≥130/85 mm Hg 
2-Hour post glucose 
challenge 
≥140 mg/dL 
Fasting glucose Between 110 and 126 mg/dL 
Other risk factors Family history of type 2 diabetes, 
hypertension, or CVD, 
Polycystic ovary syndrome, Sedentary 
lifestyle ,Advancing age, 
Ethnicgroups having high risk for 
diabetes/CVD 
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One of the problems though is that no defined number of risk factors is specified and 
diagnosis is left to clinical judgment. 
COMPARISON OF THE 5 SETS OF DIAGNOSTIC CRITERIA 
CRITERIA WHO 1999 EGIR 1999 
AACE 
2003 
NCEP 
ATP III 
2005 
IDF 
2006 
PREREQUISITE 
Insulin 
resistance 
Insulin 
resistance OR 
fasting 
hyperinsuline
mia 
Insulin 
resistance 
in the top 
25%; 
glucose≥1
10 mg/dL; 
2 hour 
glucose≥1
40 mg/dL 
 Waist≥ 
94 cm in 
Europid 
men and 
≥ 80 cm 
in 
Europid 
women 
Number of criteria 
Above & 
≥2 of the 
below 
Above & 
≥2 of the below 
Above & 
≥2 of the 
below 
≥3 of the 
below: 
Above 
& ≥2 of 
the 
below 
Waist 
circumference 
waist: hip 
ratio >0.9 
in men, 
>0.85 in 
women 
≥ 94 cm 
(male), ≥ 
80 cm 
(female) 
 
 >102 cm 
(male); 
 > 88cm 
(female) 
≥ 94 cm 
in 
Europid 
men 
and ≥ 
80 cm 
in 
Europid 
women  
Blood pressure 
≥140 mm 
Hg 
systolic or 
≥90mm 
Hg 
diastolic 
≥ 140/90 
mmHg or 
antihypertensi
ve medication 
 
≥130/85 
mm Hg 
≥130/≥8
5mm Hg 
≥130/85 
mm Hg 
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CRITERIA 
WHO 
1999 
EGIR 1999 
AACE 
2003 
NCEP 
ATP III 
2005 
IDF 
2006 
Fasting blood 
glucose 
 110-125 
mg/dL 
≥110 
mg/dL; 2 
hour 
glucose≥1
40 mg/dL 
≥110 
mg/dL 
Or on 
treatmen
t for  
elevated 
blood 
glucose 
≥110 
mg/dL 
Or 
diagnos
ed 
diabetes 
Triglycerides 
≥150 
mg/dL 
 ≥ 2.0 mmol/L 
and/or or 
treated for 
dyslipidemia 
≥150 
mg/dL 
≥150 
mg/dL 
≥150 
mg/dL 
HDL cholesterol 
<35 
mg/dL in 
men or 
<39 
mg/dL in 
women 
 < 1.0 mmol/L < 40 
mg/dL in 
men or < 
50 mg/dL 
in women 
< 40 
mg/dL 
in men 
or < 50 
mg/dL 
in 
women 
< 40 
mg/dL 
in men 
or < 50 
mg/dL 
in 
women 
All of the five above mentioned are sets of criteria for defining the metabolic 
syndrome. Though similar conceptually, there are some significant disparities. 
 One of the major criticisms of the WHO criteria is the inclusion of diabetes mellitus 
as a criterion in diagnostic system intended for the identification of those at risk of 
developing diabetes mellitus. The need for doing the oral glucose tolerance test makes 
it impractical and expensive without any added benefit in diagnostic predictability. 
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Use of the NCEP criteria fails to identify those people on treatment for dyslipidemia 
or hypertension. It also suffers from the same problem as the WHO criteria with 
respect to the inclusion of diabetes mellitus as one of the criterion. 
The IDF on the other hand takes into account treatment for hypertension and 
dyslipidemia in the criterions. It also provides ethnic specific values for the 
measurement of waist circumference. However, it too fails to exclude diabetes 
mellitus as a criterion. 
ATP III metabolic syndrome criteria were updated in 2005(35,36). Updates included : 
• Lowering the threshold for abnormal fasting glucose to 100 mg/dL 
• Explicitly including diabetes in the hyperglycemia trait definition 
• Explicitly including use of drugs for lipid control or blood pressure control in 
the dyslipidemia and hypertension trait definitions, respectively 
Joint Interim Statement 
Taking into account the various diagnostic criteria proposed by different 
organizations, a meeting between the major organizations was held in an attempt to 
unify the criteria(37). It was agreed that waist measurement would continue to be a 
useful preliminary screening tool. Three out of five would qualify a person for the 
metabolic syndrome. A single set of cut points would be used for all components 
except for waist circumference. 
 
 
 
 
 
33 
 
Joint Interim Statement Criteria for Clinical Diagnosis of the Metabolic 
Syndrome 
 
                               
                           Measure 
 
         Categorical Cut Points 
 
Elevated waist circumference* Population- and 
country-specific definitions 
 
Elevated triglycerides (drug 
treatment 
for elevated triglycerides is an 
alternate indicator†) 
 
≥150 mg/dL (1.7 mmol/L) 
 
Reduced HDL-C (drug treatment for 
reduced HDL-C is an alternate 
indicator†) 
 
< 40 mg/dL (1.0 mmol/L) in 
males; 
< 50 mg/dL (1.3 mmol/L) in 
females 
 
Elevated blood pressure 
(antihypertensive drug treatment in 
a 
patient with a history of 
hypertension 
is an alternate indicator) 
 
Systolic _130 and/or diastolic 
≥85 mm Hg 
 
Elevated fasting glucose‡ (drug 
treatment of elevated glucose is an 
alternate indicator) 
 
≥100 mg/dL 
 
 
 
HDL-C indicates high-density lipoprotein cholesterol. *It is recommended that the IDF cut 
points be used for non-Europeans and either the IDF or AHA/NHLBI cut points used for 
people of European origin until more data are available. †The most commonly used drugs for 
elevated triglycerides and reduced HDL-C are fibrates and nicotinic acid. A patient taking 1 
of these drugs can be presumed to have high triglycerides and low HDL-C. High-dose _-3 
fatty acid presumes high triglycerides. ‡Most patients with type 2 diabetes mellitus will have 
the metabolic syndrome by the proposed criteria.(37) 
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Prevalence of metabolic syndrome in the general population 
 The prevalence of metabolic syndrome worldwide ranges from as high as 24% in the 
United States of America to as low as 8% in India (12).  One study showed that the 
variation in the prevalence rates in women can range from 7% in France to 43% in 
Iran(12). There is also an age related increase in the prevalence of metabolic 
syndrome in both men and women in the USA. 
An assessment by the International Diabetes Federation found that 25 % of the 
world’s population has metabolic syndrome. Studies have shown that there is 
variability in the prevalence rates based on gender, racial and ethnic differences(19). 
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Prevalence of the metabolic syndrome according to the ATP III definition 
Country Age group (years) Reference 
Prevalence 
(%) Men 
Prevalence 
(%) Women 
India >20 Gupta et al (38) 7.9 17.5 
India 20–75 Deepa et al (39)  36.4a 46.5a 
Iran >20 Azizi et al 24 42 
Mexico 20–69 Aguilar-Salinas 
et al (40)                      Total = 26.6  
Oman >20 Al-Lawati et al (41)  19.5 23.0 
Finland 42–60 Laaksonen et al 13.7 — 
Ireland 50–69 Villegas et al  21.8 21.5 
Scotland 45–64 Sattar et al  26.2 — 
Turkey >31 Onat et al 27.0 38.6 
Australia >24 Unpublished data 19.5 17.2 
Mauritius >24 Cameron et al (41)  10.6
a
 14.7a 
France 30–64 Balkau et al 10 7 
United States 
(Native 
Americans) 
45–49 Resnick et al  43.6 56.7 
United States 
(Filipina 
Americans) 
50–69 Araneta et al  — 34.3 
United States >19 Ford et al  24.2 23.5 
United States 30–79 Meigs et al  26.9 21.4 
United States 
(Non-
Hispanic 
white) 
30–79 Meigs et al  24.7 21.3 
United States 
(Mexican 
American) 
30–79 Meigs et al  29.0 32.8 
a- Obesity criteria adjusted to waist circumference appropriate for an 
Indian population. 
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Prevalence of the metabolic syndrome according to the WHO definition 
Country Age group (years) Reference 
Prevalence 
(%) Men 
Prevalence (%) 
Women 
Australia >35 Unpublished data 25.2 16.7 
Denmark 60 Balkau et al  38.0 22.0 
England 40–65 Balkau et al  >44.8 >33.9 
England 40–75 Balkau et al  >12.6 >13.3 
France 30–65 Balkau et al  >23.5 >9.6 
France 35–64 Marques-Vidal et al 23.0 12.0 
Italy 22–73 M, 22–55 F Balkau et al  >12.2 >5.1 
Italy 40–81 M, 40–55 F Balkau et al 34.5 18.0 
Netherlands 20–60 Balkau et al  >19.2 >7.6 
Spain 35–64 Balkau et al  >25.5 >19.9 
Sweden 46–68 Balkau et al  43.3 26.3 
Mauritius >24 Cameron et al  20.9 17.6 
Occupied 
Palestinian 
Territories 
30–65 Abdul-Rahim 
et al                         Total = 17 
Ireland 50–69 Villegas et al  24.6 17.8 
United States 40–74 Ford et al  41.3 32.7 
United States 30–79 Meigs et al  30.3 18.1 
United States 
(non-Hispanic 
white) 
30–79 Meigs et al 24.7 17.2 
United States 
(Mexican 
American) 
30–79 Meigs et al  32.0 28.3 
Abbreviations: F, female; M, male. 
A “greater than” sign (>) means that the figure is an underestimate because 
one or more components of the metabolic syndrome were not measured. 
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Prevalence of the metabolic syndrome according to the EGIR definition 
Country Age group (years) Reference 
Prevalence 
(%) Men 
Prevalence 
(%)  Women 
India >20 Deepa et al  12.9 9.9 
Finland 42–60 Laaksonen et 
al  21.1 – 
Australia >24 Unpublished data 18.6 13.3 
Denmark 60 Balkau et al  22.0 16.0 
England 40–65 Balkau et al  17.9 14.3 
England 40–75 Balkau et al  4.7 3.9 
France 30–65 Balkau et al  16.4 10.0 
Italy 22–73 M,  22–55 F Balkau et al  8.7 1.7 
Italy 40–81 M,  40–55 F Balkau et al  24.6 14.0 
Netherlands 20–60 Balkau et al  13.3 8.3 
Spain 35–64 Balkau et al  16.0 15.4 
Sweden 46–68 Balkau et al  23.6 13.9 
Mauritius >24 Cameron et al  9.0 10.2 
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Prevalence of metabolic syndrome (MetS) in people with schizophrenia(42) 
Study Country N Design Mean 
age 
% 
MetS Criteria 
Heiskanen et 
al (78) Finland 35  44.5 37.1 ATP III 
Almeras et al 
(62) Canada 42 Olanzapine 31.7 33.0 ATP III 
 Canada 45 Risperidone 28.4 11.0  
Basu et al (65) USA 33 Schizoaffective disorder 44.5  42.4 ATP III 
Cohn et al 
(68) Canada 240  42.7 44.6 ATP III 
Kato et al (80) USA 48  40.3 63.0 ATP III 
Straker et al 
(96) USA 89  39.8 29.2 ATP III 
Meyer et al 
(83) USA 1231  42.8 35.8 ATP III 
McEvoy et al 
(82) USA 342 White males  39.8 40.9 ATP III 
  92 White females 44.2 56.2 ATP III 
Saari et al (88) Finland 31  31.0 19.4 ATP III 
Correll et al 
(69) USA 367  42.9 37.3 ATP III 
De Hert et al 
(71) Belgium 430  36.5 32.3 ATP III-A 
De Hert et al 
(72) Belgium 415  37.7 33.3 IDF 
  100 
First episode 
(maximal 
duration 2 year 
illness) 
25.7 17.0 IDF 
  130 Duration illness 
<10 years 29.0 28.5 IDF 
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Study Country N Design Mean 
age 
% 
MetS Criteria 
  106 Duration illness 10 to 20 years 39.0 42.4 IDF 
  79 Duration illness 
>20 years 49.8 49.4 IDF 
Hagg et al 
(77) Sweden 269  46.0 34.6 ATP III 
Lamberti et al 
(81) USA 93 Clozapine 34.4 53.8 ATP III 
Srisurapanont 
et al  Thailand 38  53.7 36.2 ATP III 
(95)  44  44.3 31.8 ATP III-A 
Suvisaari et al 
(97) Finland 108  34.6 34.0 ATP III-A 
Teixeira and 
Rocha  Brazil 122 
First episode, 
before treatment 
with FGA 
23.1 5.7 ATP III-A 
(98)  122 First episode, 3 year FGA 26.8 13.1 ATP III-A 
Cerit et al (67) Turkey 108 
First episode, 
before treatment 
with SGA 
21.9 5.6 ATP III-A 
De Hert et al 
(74) Belgium 108 
First episode, 3 
year SGA 25.1 31.6 ATP III-A 
  2270  41.0 33.9 ATP III-A 
De Hert et al 
(75) Europe 58  36.3 40.0 ATP III-A 
Ellingrod et al 
(76) USA 99 
First episode 
after treatment  26.1 18.2 IDF 
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Incidence of metabolic (MetS) in people with schizophrenia(42) 
Study Country N Design Mean 
age 
% 
MetS Criteria 
De Hert et al 
(71) Belgium 31 
Baseline 
aripiprazole 36.7 61.3 ATP III-A 
   
Endpoint 
aripiprazole 36.7 29.0 ATP III-A 
Attux et al (64) Brazil 44 First episode 6 
months 26.3 6.8 ATP III 
De Hert et al 
(73) Belgium 155 
After 3 months 
SGA 33.7 18.7 ATP III-A 
  16 After 3 months 
amisulpride 33.7 6.3 ATP III-A 
  16 After 3 months 
aripiprazole 33.7 0.0 ATP III-A 
  20 After 3 months 
clozapine 33.7 45.0 ATP III-A 
  45 After 3 months 
olanzapine 33.7 24.4 ATP III-A 
  21 After 3 months quetiapine 33.7 19.1 ATP III-A 
  37 After 3 months 
risperidone 33.7 10.8 ATP III-A 
’Italien et al 
(79) USA 91 
Placebo trials, 
placebo 41.4 14.3 ATP III 
  151 Placebo trials, 
aripiprazole 40.7 5.3 ATP III 
  212 
Active 
comparator 
trials, 
Olanzapine 
37.7 27.4 ATP III 
  198 
Active 
comparator 
trials, 
Aripiprazole 
37.6 15.7 ATP III 
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Study Country N Design Mean 
age 
% 
MetS Criteria 
Saddichha et al 
(89) India 30 
First episode 6 
weeks 26.9 27.5 IDF 
Srisurapanont 
et al (95) Thailand 35 
Naturalistic 1 
year follow-up 34.7 20.0 IDF 
De Hert et al 
(74) Belgium 122 
First episode, 3 
year FGA 26.8 9.8 ATP III-A 
  108 First episode, 3 year SGA 25.1 27.8 ATP III-A 
  8 
First episode, 3 
year 
Amisulpride 
25.1 12.5 ATP III-A 
  10 
First episode, 3 
year 
Aripiprazole 
25.1 0.0 ATP III-A 
  12 First episode, 3 year clozapine 25.1 50.0 ATP III-A 
  34 First episode, 3 year Olanzapine 25.1 41.3 ATP III-A 
  24 First episode, 3 year quetiapine 25.1 12.6 ATP III-A 
  20 First episode, 3 year Risperidone 25.1 10.2 ATP III-A 
Meyer et al 
(84) USA 164 
Baseline 
olanzapine 40.9 34.8 ATP III-A 
   
After 3 months 
olanzapine 40.9 43.9 ATP III-A 
  147 Baseline 
risperidone 40.9 30.6 ATP III-A 
   
After 3 months 
risperidone 40.9 30.6 ATP III-A 
  143 Baseline quetiapine 40.9 37.8 ATP III-A 
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Study Country N Design Mean 
age 
% 
MetS Criteria 
   
After 3 months 
quetiapine 40.9 37.1 ATP III-A 
  77 
Baseline 
ziprasidone 40.9 37.7 ATP III-A 
   
After 3 months 
ziprasidone 40.9 29.9 ATP III-A 
  129 Baseline perphenazine 40.9 37.2 ATP III-A 
   
After 3 months 
perphenazine 40.9 38.0 ATP III-A 
Schorr et al 
(93) Netherlands 260 
12 months 
incidence 41.0 14.0 ATP III 
   
12 months 
reversibility 37.0 33.0 ATP III 
 
Management of Metabolic Syndrome 
Since the prevalence of metabolic syndrome is as high as 25% of the world 
population, methods to effectively manage this syndrome should take a priority. As 
part of good clinical practise, prevention of metabolic syndrome should be targeted. 
The first step in prevention would be the identification of risk factors for metabolic 
syndrome (18). The prevention strategies should include diet modifications, lifestyle 
changes, weight loss and judicious use of pharmacological agents.(19) 
Educational interventions should be based on client centred approach where the focus 
should be on eliciting the patient’s knowledge of the syndrome and the understanding 
of the role of physical exercise and diet in its management.  Effective treatment 
should include helping the patient set short term and long term targets and aid in 
providing consistent motivation to attain these set goals. Pharmacological strategies 
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should be resorted to only when the non-pharmacological strategies fail (19). 
Numerous studies have emphasised on the role of weight reduction strategies. General 
recommendations are to target weight loss of at least 10% during the initial six 
months to a year. Weight reduction strategies need to continue until the BMI is less 
than 25(9). 
The pharmacological strategies recommended in weight reduction are mainly based 
on two modes of action: 
• Appetite suppressants 
• Inhibitors of nutritional absorption 
Appetite suppressants: Sibutramin and phentermine derivatives reduce appetite in the 
afternoon and evening if administered early in the morning. 
Nutritional Absorption Inhibitor:  Orlistat is found to reduce fat absorption by 30 %. It 
is recommended for use as a single agent at a time (20). 
The success of weight loss programs is based on the inclusion of regular exercise in 
the program. Daily regular exercise has been shown to independently reduce the risk 
factors for metabolic syndrome (12). 
Metabolic Syndrome and Mental Illness 
The life expectancy of people with chronic and severe mental illnesses like 
schizophrenia is lower than the general population(43–46). In addition to this the 
mortality rates are two to three times higher than the general population. Moreover, 
over the past decades the mortality gap has been widening (47). In people with severe 
mental illness the risk of dying secondary to a cardiovascular event is nearly twice 
that of the general population (30–34). 
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Awareness about the high rates of morbidity and mortality among people with severe 
mental illness has led in the recent decades to alarm bells ringing  about the nature of 
physical co-morbidities in severely mentally ill populations(48–50). Though the 
presence of multiple physical co-morbidities is of significance, another factor 
contributing to the morbidity and mortality rates is the poor access to good quality 
health care (51). 
 
The risk factors for metabolic syndrome can also be attributed to the poor diet, 
sedentary habits and lifestyle prevalent among people with mental illness. There has 
also been an increasing awareness among clinicians about the contribution of 
antipsychotic medications in the incidence of metabolic syndrome (48–50). The 
changes in the metabolic profile of patients have been linked to the dose of the 
antipsychotic agent as well (52). 
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Studies on the prevalence of metabolic syndrome 
Study Country Methodology Sample Size 
Criteria 
For 
Mets 
Prevalence 
In drug 
Naive 
patients 
(%) 
Comments 
Grover 
et al 
(53) 
India 
Cross sectional 
study on patients 
with 
schizophrenia 
without any 
controls 
46 IDF ATP III 
10 (IDF) 
13 (ATP 
III) 
No controls 
Pallava 
et al(54) India 
Cross sectional 
comparative 
study on 50 anti 
psychotic naive 
and 50 anti 
psychotic 
treated patients 
50 IDF 26.0 
10 patients 
had 
received 
anti 
psychotics 
in the past 
Patel et 
al(55) USA 
52 weeks follow 
up of patients 
with early 
psychosis using 
double blind, 
flexible dose, 
multisite design 
400 ATP III 4.31 
Incidence 
of 
metabolic 
syndrome 
one year 
post 
treatment 
was 13.4% 
Padmav
ati et 
al(56) 
India 
Never treated 
patients with 
chronic 
schizophrenia 
versus healthy 
controls 
51 IDF 3.8 
Prevalence 
of 
metabolic 
syndrome 
7.8% in 
controls 
De Hert 
et al(42) Belgium 
First cohort: 
retrospective 
chart review of 
1st episode 
schizophrenia at 
baseline and after 
3 years of FGA 
148 ATP III 4.7 
Prevalence 
of 
metabolic 
syndrome 
13.1% after 
3 years 
Second cohort: 
prospective 
naturalistic 
follow up study 
of 1st episode 
schizophrenia at 
baseline and after 
3 yrs of SGA 
148 ATP III 5.4 
Prevalence 
of 
metabolic 
syndrome 
30.6% after 
3 years 
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Study Country Methodology Sample Size 
Criteria 
For 
Mets 
Prevalence 
In drug 
Naive 
patients 
(%) 
Comments 
Saddich
a et al 
(57) 
 
India 
Drug naive 1st 
episode 
schizophrenia 
followed up 
over 6 weeks on 
Olanzapine or 
Risperidone 
using double 
blind design 
30 IDF 3.3 
Prevalence 
of 
metabolic 
syndrome 
31.8% after 
6 weeks 
treatment 
FGA-first generation antipsychotic, SGA- second generation antipsychotic, IDF-
International Diabetes Federation, ATP III-Adult Treatment Panel III, MetS-Metabolic 
syndrome 
 
In the general population, metabolic syndrome is a strong predictor of diabetes 
mellitus, cardiovascular disease and mortality(58). 
The concept of metabolic syndrome has become well recognized in the psychiatric 
circles. This has subsequently led to increasing the awareness in the mind of the 
clinical psychiatrist on the importance of screening for metabolic risk factors in 
patients being treated with antipsychotic medications(59,60). 
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Relationship between second generation antipsychotic medications and 
metabolic abnormalities(61–63)  
 
DRUG WEIGHT GAIN 
RISK FOR 
TYPE 2 
DIABETES 
MELLITUS 
WORSENING 
LIPID PROFILE 
CLOZAPINE +++ +++ +++ 
OLANZAPINE +++ +++ +++ 
RISPERIDONE ++ ++/+ + 
QUETIAPINE ++ ++ ++/+ 
ARIPIPRAZOLE
* 
+/- +/- + 
ZIPRASIDONE* +/- + + 
AMISULPRIDE* +/- - - 
PALIPERIDONE
* 
+ + + 
ASENAPINE* ++/+ + D 
ILOPERIDONE* ++/+ + D 
BIFEPRUNOX* +/- +/- D 
Abbreviations- + : increased effect; - :no effect; D: discrepant results;*: newer 
drugs with limited long term data. 
 
In the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial one 
third of the patients met the NCEP criteria for metabolic syndrome at baseline 
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(64,65). Of them 88% had dyslipidemia, 62% had hypertension and 38% had diabetes 
mellitus while not on treatment(65) . There is significant difference between 
individual antipsychotic agents effects on weight, lipids and glucose metabolism 
(65,66) 
  
The commonly implicated causal factors for metabolic syndrome in Schizophrenia are 
those of lifestyle related factors, psychotic illness related factors and antipsychotic 
medication related factors. A new entrant to this group are the possible genetic causes 
for metabolic syndrome in this particular subgroup(60,64). Points emphasising this 
causality are the presence of evidence of increased liability for the development of 
metabolic syndrome in patients with schizophrenia even before the institution of 
antipsychotic medications and the increased risk among first degree relatives to 
develop diabetes mellitus (67). Studies have also shown elevated levels of cortisol and 
blood sugars along with visceral adiposity even before the commencement of therapy 
with antipsychotic agents(66,68). One study highlighted a higher vulnerability in 
schizoaffective disorder as compared to schizophrenia or bipolar disorder for 
developing metabolic syndrome (69). 
 
Metabolic Syndrome and Antipsychotic medications 
Antipsychotic medications are attributed a major causal role in the incidence of 
metabolic syndrome in the mentally ill population. Though all antipsychotic 
medications have potential to cause weight gain, there is variable difference in the 
propensity to cause weight gain that is clinically relevant (>7% increase) (70). 
Associations between the receptor profile of antipsychotic agents and their propensity 
to cause metabolic changes have been studied. Some researchers propose that this 
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variability in the receptor profiles is responsible for the differential liability to induce 
metabolic changes(66,70). Antagonist activity on muscarinic receptors has been 
hypothesised to induce weight gain.  Effect on the dopamine reward system as an 
antagonist can facilitate appetite and hence increase weight (71). The direct effect of 
antipsychotic medication on pancreatic function has been supposed to be the cause for 
irreversibility of weight gain even after discontinuation of the medications (66,67,70). 
 
Some recent studies have shown that the child and adolescent populations are more 
prone to metabolic side effects of antipsychotic medication in comparison to adult 
populations(72,73). 
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Indian scenario  
The  prevalence of the metabolic syndrome shows variations not only between 
countries but also between ethnicities within a given region.(74,75) Since metabolic 
syndrome is a construct to identify people at increased risk of developing diabetes, the 
identification of this syndrome is of special significance in a country like India which 
has one of the largest number of people with diabetes mellitus in the world(76) . 
There has been a trend of increase in both metabolic syndrome and obesity in South 
Asian countries including India accounting for the increased rates of morbidity and 
mortality due to cardiovascular disease and diabetes mellitus(77)(78). Some estimates 
state that about one third of south Asians residing in urban settings have the metabolic 
syndrome(79). The term “South Asians” is used to identify people from India, 
Bangladesh, Bhutan, Maldives, Nepal, Pakistan, and Sri Lanka. The higher prevalence 
of diabetes mellitus among the South Asian population despite lower rates of obesity 
(when defined by the traditional body mass index criteria) is called the South Asian 
Paradox(77,78). Some researchers attribute to the peculiar phenotype of people from 
this part of the globe, called the South Asian Phenotype. This is characterised 
anthropometrically by increased waist circumference, increased waist hip ratio and 
excessive body fat mass. The classic Indian lipid triad is low levels of HDL 
cholesterol, elevated levels of triglycerides and elevated LDL cholesterol(80–82). In 
other studies the blood parameters are characterised by  increased plasma insulin 
levels, increased triglycerides, low levels of HDL cholesterol, insulin resistance and 
atherogenic dyslipidemia(77,78). Taking off from this concept one subset analysis 
which was part of the landmark Chennai Urban Rural Epidemiology Study (CURES) 
was comparison of the prevalence of coronary artery disease between metabolic 
obesity and phenotype obesity(83). This study showed initially that the prevalence of 
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coronary artery disease was higher in metabolically obese in comparison to the 
metabolically healthy obese phenotype, this difference did not hold true when age 
standardization was done(83). Independent studies on the prevalence of metabolic 
syndrome have been conducted in different parts of India (39)(84)(85)(86,87). There 
is unfortunately a dearth of periodic nationwide data and surveillance protocols in 
India to monitor metabolic syndrome(88,89). The prevalence rates vary from 18.3% 
(39) to as high as 33.5%(87). There are however differences in the diagnostic 
guidelines employed by these studies. The CURES study which is one of the largest 
epidemiological studies on diabetes conducted in India made comparison of the 
prevalence rates based on whether the WHO, IDF or ATP III guidelines were used. 
The study concluded that each of these guidelines identify different types of 
individuals and that the WHO criteria identified greater number of subjects with 
cardiovascular disease, though mainly in males(39). Most of the studies have used the 
ATP III criteria. The metabolic syndrome is found to have a higher prevalence in 
women (86,87). Other risk factors that have been identified include older age, 
inadequate fruit intake and middle to high socio-economic status (87). One study 
concluded that the elements of the metabolic syndrome  which are abnormal in 
women include increased waist circumference, elevated BMI, low HDL cholesterol 
and hyperglycaemia while in men these were predominantly elevated triglycerides 
and hypertension(86). 
Early death in mental illnesses like Schizophrenia has been attributed to 
cardiovascular diseases(46,90). A number of studies have been conducted in India on 
the prevalence of metabolic syndrome in antipsychotic naive patients with 
schizophrenia(53,54,56,57,91–95). These have had limitations in terms of small 
sample sizes and heterogeneity in diagnostic criteria used to define the metabolic 
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syndrome. One recent study pooled the information from the existing studies(96). 
This included pooled data from the northern(53,54,92), central(57,93,94) and 
southern(56,95) regions of India.  Using the joint interim statement guidelines(37), 
this study has shown that one fifth of patients with schizophrenia from India who are 
antipsychotic naive have metabolic syndrome(96). 
 
Metabolic profile in Antipsychotic naive Indian patients (pooled data)(96) 
Variable Total (n=137) Frequency (%) 
Male (n=69) 
Frequency (%) 
Female (n=68) 
Frequency (%) χ
2
 
value 
1*P<0.05; **P<0.01, ***P<0.001. 
1. †Fisher's exact test. 
2. BMI, body mass index; HDL, high-density lipoprotein. 
Systolic blood 
pressure 
≥130mmHg 
33 (24.1) 18 (26.0) 15 (22.1) 0.30 
Diastolic blood 
pressure 
≥85mmHg 
27 (19.7) 19 (27.5) 8 (11.8) 5.38* 
Abnormal blood 
pressure 
(≥130//≥85) or 
diagnosed as 
hypertensive 
37 (27.0) 21 (30.4) 16 (23.5) 0.82 
Triglyceride 
levels ≥150mg 
or on lipid-
lowering agents 
24 (17.5) 18 (26.1) 6 (8.8) 7.06** 
Lower HDL 
(<40mg M, 
<50mg F) or 
on lipid-
lowering agents 
81 (59.1) 31 (44.9) 50 (73.5) 11.59** 
Fasting blood 
glucose levels 
≥100mg % or 
diagnosed as 
diabetes 
mellitus 
28 (20.4) 15 (21.7) 13 (19.1) 0.14 
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Variable Total (n=137) Frequency (%) 
Male (n=69) 
Frequency (%) 
Female (n=68) 
Frequency 
(%) χ
2
 value 
Abnormal waist 
circumference 
(≥90cm for men 
and ≥80 cm for 
women) 
38 (27.7) 15 (21.7) 23 (33.8) 2.49 
Obesity 
(BMI≥25 Asian 
cut-off) 
25 (18.2) 16 (23.2) 9 (13.2) 2.27 
Underweight 
(BMI<18.5) 51 (37.22) 22 (31.8) 29 (33.8) 1.69 
Metabolic 
syndrome 
(common 
criteria for 
clinical 
diagnosis) 
26 (19) 13 (18.8) 13 (19.1) 0.002 
No. of 
metabolic 
syndrome 
criteria† 
    
0 23 (16.8) 14 (20.3) 9 (13.2) – 
1 56 (40.9) 27 (39.1) 29 (42.6) – 
2 32 (23.3) 15 (21.7) 17 (25) – 
3 21 (15.3) 11 (15.9) 10 (14.7) – 
4 2 (1.5) 1 (1.4) 1 (1.5) – 
5 3 (2.2) 1 (1.4) 2 (2.9) – 
 
Studies from India on the prevalence of metabolic syndrome in patients on 
antipsychotic medications are limited. Most studies have reported a prevalence rate 
ranging from 3.3 to 68% with an average of 35%  irrespective of the diagnostic 
guideline used to define the metabolic syndrome(91)(97). One recent study clearly 
demonstrated the increase in the prevalence when maximum dosages of antipsychotic 
medications were used(98). One other study reaffirms the current understanding of 
increased risk of metabolic syndrome with the use of Olanzapine in particular when 
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compared to other second generation antipsychotic medications(99). Majority of the 
studies have used cross-sectional design(100,101). Prospective interventional studies 
in India are few (99,102–104). These studies were of short durations ranging from 6 
weeks to 4 months. Most of them were done on patients with schizophrenia 
(53,93,99,100,103).  
Two studies have been done on metabolic syndrome in people with bipolar illness, 
which have identified central obesity as key risk factor and the prevalence to be 
higher than in patients with schizophrenia(101,102). 
 
Attrition rates in Psychiatric clinical trials 
Longitudinal studies have reported large attrition rates in clinical trials among 
psychiatric populations (105–107). Numerous variables have been described to be risk 
factors towards attrition from psychiatric clinical trials. These are broadly divided into 
socio-demographic variables, lifestyle variables and psycho-pathology related 
variables.  Some studies have enumerated low educational level, unemployed status, 
being single or divorced as the socio-demographic variables that lead to high rates of 
attrition (107–109).  Unhealthy lifestyle variables described in literature to be 
associated with high attrition rates include lack of physical activity, use of tobacco 
and alcohol (109–111). Studies have also highlighted high rates of attrition among 
psychiatric patients with previous history of hospitalization and in those using 
outpatient facilities (106,112). Types of attrition have been categorised into refusal, 
non-contact and death. Non-contact can be of two types: those who were unable to 
participate and those who could not be contacted. An understanding of the 
mechanisms underlying these types of attrition gives insight into the determinants 
involved (113). Research has shown that being of younger age, lesser degree of 
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formal education, no prior history of participation in research and having depressive 
illness as determinants associated with drop out in European population (114). No 
major differences have been found between the effects of these determinants on the 
type of attrition. People with depressive and anxiety illnesses have been reported to be 
at 2.4 times higher risk of dropping out (114). 
 
Screening and Monitoring guidelines in Psychiatric population 
At the onset of initiating therapy with antipsychotic medications, prevention of the 
development of metabolic syndrome should be given high priority. Hence the 
initiation of exercise, diet and lifestyle modification strategies should start 
prophylactically, while the medication is being started. 
There is a lack of consensus regarding the responsibility to mentally ill patients 
regarding general health care. This is reflected in the failure to provide adequate and 
appropriate health care to this subset of the population. In routine practise the 
psychiatrist’s main focus is on the effectiveness of the antipsychotic therapy. As a 
result the general medical needs of the patient are inadvertently neglected.  
In spite of the numerous national and international guidelines for monitoring of 
metabolic syndrome, these are rarely enforced in routine clinical practise (115–117). 
Assessment of the metabolic risk profile before the initiation of antipsychotic therapy 
is important. The sensitivity in identifying patients with metabolic syndrome using 
waist circumference and fasting glucose measures is as high as 100%. This 
emphasises that cardio-metabolic risk profile assessment is a must before the 
commencement of treatment (118). 
In order to prevent the metabolic complications the non-pharmaceutical interventions 
like lifestyle interventions, diet modifications and physical exercise regimen need o be 
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started early in therapy (46). Timely institution of these interventions reduces the risk 
significantly. Cessation of smoking reduces the prevalence of cardiovascular disease 
by 50-70%. Reducing the cholesterol levels by 10% bring about a 30% reduction in 
the cardiovascular disease risk. Similarly a 15% reduction in the cardiovascular risk 
can be obtained by reducing the blood pressure by 6%.  The cardiovascular disease 
risk can be reduced by 30 to 50% by combined strategies of a 20 minutes brisk walk a 
day coupled with maintaining the body mass index below 25 (46).  
 
The role of regular physical activity in reducing both cardiovascular disease and 
metabolic risk is undisputed (119).  In the prevention of dyslipidemia, diabetes, 
hypertension and obesity, regular physical activity is of great importance (120, 121).  
Hence lifestyle modification interventions in schizophrenia should incorporate regular 
physical exercise. Though the guidelines do not give recommendations to the type and 
duration of the physical activity for patients with schizophrenia, 30 minutes brisk 
walk on at least 5 days a week should suffice to reduce the metabolic risk 
significantly. Ample attention should be paid to the patient’s personal preference and 
attitude towards physical activity while selecting the activity (119,122). 
 
Interventions to stop cigarette smoking are also of great importance in the prevention 
of metabolic syndrome (123). Awareness should be present in the clinicians mind 
regarding patients who are elderly, with family history of metabolic risk factors and or 
are of ethnic group with high susceptibility for metabolic syndrome, while prescribing 
antipsychotic medication (123). 
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Once a patient develops metabolic syndrome, switching to a different antipsychotic 
medication that has reduced potential to cause metabolic effects should be the strategy 
employed. Along with this, measures to reduce cholesterol and triglycerides along 
with controlling the blood sugar and blood pressure should be put in place. During 
this process, consultation with a specialist should be sought as and when required. 
Though there is recent evidence of the efficacy and safety of statins in patients with 
schizophrenia on antipsychotic medications, their role in reversing the metabolic 
syndrome is not very significant (124,125). 
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OBJECTIVES AND AIMS 
Primary Objectives: 
• To estimate the prevalence of metabolic syndrome in antipsychotic naïve 
psychiatric patients at the recruitment phase as defined by the National 
Cholesterol Education Program’s Adult Treatment Panel III and to compare 
with the International Diabetes Federation criteria. 
• To estimate the incidence of metabolic syndrome in antipsychotic naïve 
patients, 3 months after the initiation of therapy with antipsychotic medication 
using the guidelines as defined by the National Cholesterol Education 
Program’s Adult Treatment Panel III. 
Secondary Objectives: 
• To identify the risk factors associated with metabolic syndrome in 
antipsychotic naïve patients. 
• To identify the risk factors that predicts the emergence of metabolic syndrome 
after initiation of antipsychotic therapy. 
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METHODOLOGY 
Setting:  
The study was conducted in the Department of Psychiatry, Christian Medical College 
Vellore. This is a tertiary care teaching hospital in the southern part of India. This 
facility has an in-patient capacity of 122 beds including adult, child and adolescent 
services. There is an acute care room comprising of 12 beds. Most of the patients are 
self referred and come from all over India. 
The facilities also include well equipped outpatient department, occupational therapy, 
pharmacy services and emergency services. The outpatient department functions six 
days in a week. Here both new and review patients are seen and followed up. 
Emergency services are available 24 hours a day, seven days a week. 
The institution has the facilities of a tertiary care referral centre. In addition to this it 
serves as the nearest psychiatric centre for a radius of   150 miles. The department has 
four units, two serving the needs of adult clients, one for children & adolescents and 
one for rehabilitation services. Every year this centre caters to the needs of   11000 
new patients and 90000 review patients. Per annum on an average 1000 patients are 
provided inpatient treatment services. 
Participants:  
Subjects for the study were recruited from both in-patient and out-patient facilities in 
the department of Psychiatry. Attempts were made to follow up these patients over 3 
months period. A follow up period of 3 months was chosen as there is evidence that 
the metabolic changes due to antipsychotic treatment are seen as early as around 3 
months of treatment(126,127).  
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Inclusion criteria: 
1) Age between 18 and 65 years 
2) Any patient who is antipsychotic naive and is started on antipsychotic 
medication 
3) As the patients need to be followed up after 3 months, for logistic reasons, 
participants will only be recruited from the state of Tamil Nadu. 
Exclusion criteria 
1) Age lesser than 18 and above 65 years 
2) Pre-existing metabolic syndrome 
3) Patients on combinations of antipsychotic medications with mood 
stabilizers or tricyclic antidepressants or Mirtazapine, which may 
contribute to the incidence of metabolic syndrome. 
4) Those who could not participate either due to the severity of illness or 
refusal to take part 
Variables: 
Variables assessed included  
1. Socio-demographic: age, sex, marital and employment status 
2. Individual metabolic parameters 
3. Family history of medical morbidity ( diabetes mellitus, hypertension, 
dyslipidemia, obesity) 
4. Antipsychotic medication: type and dose 
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Institutional Review Board: 
The approval of the Institutional Review Board of the Christian Medical College- 
Vellore was obtained before the commencement of the study. 
Data Sources/measurement:  
Patients attending the psychiatric OPD, inpatient and emergency services were 
screened. Those meeting the inclusion criteria were enrolled into the study after 
obtaining a written informed consent. 
Demographic data including age, sex, occupational and marital status, substance use, 
family history of medical illness was collected from the patient and relative.  
Subsequently blood pressure, height, body weight and waist circumference were 
measured and documented. 
Blood pressure measurement (128): Mercury sphygmomanometer was used for the 
measurement of the blood pressure. Patients were require to be seated quietly for at 
least 5 minutes in a chair with back supported, legs uncrossed and upper arm bared. 
Patient’s arm was supported at heart level. Measurement was taken with a cuff size 
that was appropriate to the size of the upper right arm. The right arm was preferred for 
consistency and comparison with the standard tables. The bell of the stethoscope was 
lightly placed over the brachial artery pulse, proximal and medial to the cubital fossa, 
and below the bottom edge of the cuff (i.e., about 2 cm above the cubital fossa). The 
cuff was inflated to 30 mm Hg above palpated SBP and deflated at a rate of 2 to 3 mm 
Hg/second. Both Systolic Blood Pressure (SBP) and Diastolic Blood Pressure were 
recorded. The first appearance of sound (phase 1) was used to define SBP. The 
disappearance of sound (phase 5) was used to define DBP in adults. Two or more 
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readings separated by 2 minutes were averaged. If the first two readings differ by 
more than 5 mm Hg, additional readings were obtained and averaged. Subject as well 
as the examiner did not talk during the procedure. 
Waist circumference (129): The same standardized tape was used for each 
measurement. Subject was required to stand with feet positioned close together, arms 
at the sides, erect with weight distributed evenly. The subject was advised to relax and 
take a few natural breaths before actual measurement is made. Measurement was 
made at the end of each expiration (when lungs are at their functional residual 
capacity).  Tape measurement (in centimetres) was taken with the tape aligned at 
points immediately above the iliac crests on either side. The tape was snugly pulled 
around the waist but not too tight that it was constricting. In compliance with the IDF 
criteria we also measured the waist circumference in a horizontal plane across the 
umbilicus, midway between the inferior margin of the ribs and the superior border of 
the iliac crest.  
Weight and height were also measured using the same calibrated analogue weighing 
scale and wall-meter respectively. During the measurement of weight it was ensured 
that the participants were barefooted, bareheaded, without any items of weight on 
their body, weight evenly distributed across both feet, standing erect. While 
measuring the height, the individual was asked to stand erect, barefooted with both 
feet together adjacent to the wall meter, and looking ahead. It was ensured that the 
heels, buttocks, shoulders, and head were back against the wall and that all of those 
body parts were touching the wall. Participants were asked to tuck in their chin and 
look straight ahead. A book was placed on the subject’s head (the same book was 
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used for all subjects), pressed on to the wall meter, and the place on the wall meter 
where the bottom of the book was resting was marked.   
 Patients were asked to do fasting blood glucose and fasting triglycerides and HDL 
cholesterol within a week’s time. The blood was taken using sterile methods by a 
trained technician.  
Attempts were made to review the patients after a period of three months to repeat the 
collection of all the information collected during the enrolment phase. 
Bias: 
Consecutive patients attending the psychiatric services were recruited to reduce 
selection bias. 
Sample size: 
Sample size was calculated using a previous study which estimated the incidence of 
treatment emergent metabolic syndrome in 3 months as 11% (130). 
The following assumptions were made for the calculation of the sample size: 
 Incidence   = 11% 
Margin of error (precision)      = ±6 
Confidence level  = 95% 
Power                                          = 80% 
Drop out during follow up       = 50% 
Total required sample size = 216 
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Quantitative variables: 
Mean and standard deviation would be employed to describe continuous variables, 
while frequency distributions would be obtained for categorical data. The chi square 
test and the Student’s t-test would be used to assess the significance of associations 
for categorical and continuous variables respectively. 
 
Statistical methods: 
The paired t test would be employed to assess the change over time in continuous 
variables.  
Bi-variate analyses would be done to find factors associated with metabolic syndrome 
using either chi-square tests or independent two sample t=tests as appropriate. 
Variables with a p<0.10 would subsequently be used in the multivariable logistic 
regression analysis. Odds ratios with 95% CI would be obtained to quantify the 
association between medication and other factors.  
 
Data Collection: 
Patients were referred for the study by colleagues based on the inclusion and 
exclusion criteria. These patients were screened by the study author using the 
inclusion and exclusion criteria. At the time of screening an informed written consent 
was obtained from the patient whenever possible. Written informed consent was 
obtained from the primary care giver when the patient lacked capacity to do so. 
Contact telephone numbers to prevent attrition from the study was collected after 
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taking informed verbal consent. Thereafter the patient was given the slips for the 
blood investigations to be done in a fasting state within one week. Patients were 
recruited only if they did the blood investigations within the stipulated time period. 
Anthropometric details and other relevant data were collected only after the 
completion of the blood investigations. 
Data analysis: 
Data analysis was done using SPSS Statistic software version 20. 
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RESULTS 
Flowchart of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      314 (SCREENED) 
31 (consent not given) 
39(Did not come after index visit) 
44 (Late blood investigations) 
16 (Incomplete Blood 
investigation)   
36 (Blood investigations not done) 
28 (Metabolic syndrome present) 
89(Lost to follow up) 
9(Recruited but not completed study) 
14 (Completed study) 
 283 
  244 
 200 
 184 
 148 
  120 
  31 
8(2nd round blood tests not done) 
  23 
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A total of 314 patients were screened for the study. They were referred by colleagues 
based on the inclusion and exclusion criteria. Out of these 314 subjects, 31 declined 
consent.  135 participants could not be recruited into the study.  39 patients gave 
informed consent at the time of the index visit, but did not follow up in the outpatient 
services thereafter.  As mentioned in the methodology, patients were recruited 
contingent on the blood investigations being done within one week of the start of the 
antipsychotic medications.  44 out of the 135 patients did the blood investigations 
outside the planned cut off of a week. These blood investigations were late by one day 
to two weeks. Another 16 patients reviewed with incomplete blood investigations. 
Some had not given fasting sugars; others had not given their lipid profile.  36 patients 
did not do any of the blood investigations. 
148 patients out of the total 314 patients screened entered into the study based on the 
satisfaction of the inclusion criteria, and blood investigation requirements. Baseline 
blood investigations coupled with the anthropometric measurements revealed that 28 
out of the 148 antipsychotic naive patients had metabolic syndrome according to 
NCEP- ATP III criteria. These patients were hence removed from the cohort.   
Of the remaining 120 participants, 89 were lost to follow up in terms of not using the 
outpatient services. Attrition in terms of mortality is not known.  Attempts were made 
to reduce the attrition by calling the patient or caregivers by phone. The reasons for 
attrition included improvement in symptoms, complete resolution of symptoms and 
promises of following up which were not met. The required blood investigations were 
not done at the time of review by 8 subjects even though they continued to use the 
outpatient services and hence could not be used in the analysis. 14 patients, who were 
compliant with the medications, were followed up according to the study guidelines 
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and could be assessed for the emergence of metabolic syndrome. 9 of the 148 subjects 
had been recruited in August 2014 and were not included at the time of analysis 
(September 2014) as they would complete 3 months of antipsychotic therapy only by 
October 2014.  Data collection was incomplete due to advancement of the date of 
submission of the thesis by 2 months that was announced in July and confirmed in 
August 2014. 
A total of 148 patients were recruited into the study after obtaining written informed 
consent. 14 subjects were followed up after 3 months for incidence of metabolic 
syndrome. 28 subjects had metabolic syndrome before the start of antipsychotic 
medications. 97 subjects were lost to follow up. 9 had not completed the study period. 
 
 
 
 
 
- 
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Age distribution of the patients recruited at baseline 
 
As depicted in the histogram, the mean age of the selected sample was   35. The 
standard deviation was 12 years. The youngest recruit was 18 years old. The oldest 
participant was 65 years old. 
Out of the 148 participants who were recruited 72 were male and 76 were female. The 
mean age of the subjects was 36 years. Of the participants 44 were single, 98 were 
married, and 6 were widowed or separated. 30 subjects were illiterate while the 
remaining 118 were literate. 
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SOCIO-DEMOGRAPHIC, DIET AND SUBSTANCE USE DISTRIBUTION 
AMONG THE PATIENTS AT BASELINE 
VARIABLE 
NUMBER 
OF 
PATIENTS 
PERCENTAGE 
TOTAL 
NUMBER 
OF 
PATIENTS 
AT 
BASELINE 
 
GENDER 
MALE 72 49 
148 
FEMALE 76 51 
 
MARITAL 
STATUS 
SINGLE 44 30 
148 
MARRIED 98 66 
DIVORCED 
/ WIDOWED 6 4 
EDUCATION 
ILLITERATE 30 20 
148 
LITERATE 118 80 
DIET 
VEGETARIAN 20 13 
148 NON-
VEGETARIAN 128 87 
TOBACCO 
USE* 
ABSENT 121 82 
148 
PRESENT 27 18 
ALCOHOL 
USE* 
ABSENT 128 87 
148 
PRESENT 20 13 
 
* Use does not amount to a dependence pattern 
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Distribution according to the diet and prevalence of metabolic syndrome (NCEP-
ATP III criteria) at baseline 
NCEP- ATP III CRITERIA 
DIET 
Total 
VEGETARIAN NON-VEGETARIAN 
NCEP ATP 
Criteria 
satisfied 
Nil criteria 4 35 39 
1 criteria 7 43 50 
2 criteria 6 25 31 
3 criteria 3 25 28 
Total  20 128 148 
 
The above table illustrates the distribution of the participants at the time of 
recruitment into the study based on the type of diet and satisfaction of the NCEP-
ATPIII criteria. Statistical analysis of the association between type of diet and the 
prevalence of metabolic syndrome was done. Analysis was also done comparing type 
of diet with the prevalence sub-threshold metabolic syndrome (either satisfying only 2 
or only 1 criterion out of the 5 NCEP-ATPIII criteria). The analysis was done using 
Chi square test which gave Pearson Chi-Square value of 1.457 with Fisher’s Exact 
Test p value of 0.704. This was not statistically significant. 
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Distribution according to use of tobacco and prevalence of metabolic syndrome 
(NCEP-ATP III criteria) at baseline 
 
NCEP- ATP III CRITERIA 
TOBACCO USE 
Total 
ABSENT PRESENT 
 
NCEP ATP 
Criteria 
satisfied 
Nil criteria 36 3 39 
1 criteria 39 11 50 
2 criteria 25 6 31 
3 criteria 21 7 28 
Total  121 27 148 
 
The above table illustrates the distribution of the participants at the time of 
recruitment into the study based on the use of tobacco and satisfaction of the NCEP-
ATPIII criteria. Statistical analysis of the association between use of tobacco and the 
prevalence of metabolic syndrome was done. Analysis was also done comparing use 
of tobacco with the prevalence sub-threshold metabolic syndrome (either satisfying 
only 2 or only 1 criterion out of the 5 NCEP-ATPIII criteria). The analysis was done 
using Chi square test which gave Pearson Chi-Square value of 4.267 with Fisher’s 
Exact Test p value of 0.185. This was not statistically significant. 
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Distribution according to use of alcohol and prevalence of metabolic syndrome 
(NCEP-ATP III criteria) at baseline 
 
NCEP- ATP III CRITERIA 
ALCOHOL  USE 
Total 
ABSENT PRESENT 
 
NCEP ATP 
Criteria 
satisfied 
Nil criteria 37 2 39 
1 criteria 45 5 50 
2 criteria 24 7 31 
3 criteria 22 6 28 
Total 
 128 20 148 
 
The above table illustrates the distribution of the participants at the time of 
recruitment into the study based on the use of alcohol and satisfaction of the NCEP-
ATPIII criteria. Statistical analysis of the association between use of alcohol and the 
prevalence of metabolic syndrome was done. Analysis was also done comparing use 
of alcohol with the prevalence sub-threshold metabolic syndrome (either satisfying 
only 2 or only 1 criterion out of the 5 NCEP-ATPIII criteria). The analysis was done 
using Chi square test which gave Pearson Chi-Square value of 6.556 with Fisher’s 
Exact Test p value of 0.081. This was not statistically significant. 
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DISTRIBUTION ACCORDING TO THE PRESENCE OF FAMILY HISTORY 
OF RISK FACTORS AMONG THE PATIENTS AT BASELINE 
FAMILY HISTORY OF 
NUMBER 
OF 
PATIENTS 
PERCENTAGE 
TOTAL 
NUMBER OF 
PATIENTS 
AT 
BASELINE 
 
HYPERTENSION 
ABSENT 
138 93 
148 
PRESENT 
10 7 
 
DIABETES 
MELLITUS 
ABSENT 
136 92 
148 PRESENT 
12 8 
 
DYSLIPIDEMIA 
ABSENT 139 94 148 
PRESENT 9 6 
OTHER* 
ABSENT 145 98 148 
PRESENT 3 2 
*- These illnesses included two with family history of seizure disorder and one with 
family history of stroke. 
 
75 
 
DISTRIBUTION OF THE VARIOUS INDIVIDUAL COMPONENTS OF THE 
METABOLIC SYNDROME AMONG THE PATIENTS AT BASELINE 
Criterion Number of patients Percentage 
Total number 
of patients at 
baseline 
 
WAIST 
CIRCUMFERENCE 
NORMAL 124 84 
148 
INCREASED 
 (males ≥ 90 
cm, females  
≥ 80 cm) 
24 16 
 
BLOOD PRESSURE 
NORMAL 118 80 
148 INCREASED 
(≥130/≥85 
mm Hg) 
30 20 
FASTING BLOOD 
SUGAR 
NORMAL 116 78. 
148 
ELEVATED 
(≥100 mg/dl) 32 22. 
TRIGLYCERIDES 
NORMAL 112 76 
148 
ELEVATED 
(≥150 mg/dl) 36 24 
HDL 
CHOLESTEROL 
NORMAL 65 44 
148 
LOWERED 
(< 40 mg/dL  
males; < 50 
mg/dL 
females) 
83 56 
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Distribution of the means of the variables at the baseline 
 
VARIABLE MEAN 
STANDARD 
DEVIATION 
MINIMUM 
VALUE 
MAXIMUM 
VALUE 
AGE (years) 36 12 18 65 
WAIST 
CIRCUMFERENCE (cm) 75.85 11.9 29 106 
SYSTOLIC BLOOD 
PRESSURE (mmHg) 117.9 10.2 90 150 
DIASTOLIC BLOOD 
PRESSURE (mm Hg) 78.07 6.26 60 100 
FASTING BLOOD 
SUGAR (mg/dL) 94.7 25.77 52 272 
HDL CHOLESTEROL 
(mg/dL) 44.95 13.52 10 121 
TRIGLYCERIDES 
(mg/dL) 127.68 109 34 1018 
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Prevalence of metabolic syndrome in the patients at baseline (NCEP-ATP III 
criteria) 
METABOLIC 
SYNDROME 
NUMBER OF 
PARTICIPANTS PERCENTAGE 
ABSENT 120 81 
PRESENT 28 19 
TOTAL 148 100 
 
Analysis at the time of recruitment showed that based on the NCEP ATP III 
diagnostic criteria 19 % of the sample satisfied 3 out of the 5 criteria. This means that 
28 patients out of the 148 participants recruited had metabolic syndrome even before 
the start of antipsychotic medications.  
 
MetS-  Metabolic Syndrome absent 
MetS+ Metabolic Syndrome present 
 
Prevalence of Metabolic syndrome (NCEP ATP III criteria) among the patients at 
baseline148) 
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Gender specific distribution in the patients at baseline 
Female 
 
METABOLIC SYNDROME 
IN FEMALES 
NUMBER OF 
PARTICIPANTS PERCENTAGE 
ABSENT 62 81 
PRESENT 14 19 
TOTAL 76 100 
 
Among the 76 female members recruited at the time of the study, 14 participants had 
metabolic syndrome prior to the initiation of antipsychotic medication. This is based 
on the NCEP ATP III criteria.  This amounts to 19% prevalence rate among women. 
Male 
 
METABOLIC 
SYNDROME 
IN MALES 
NUMBER OF 
PARTICIPANTS PERCENTAGE 
ABSENT 
58 80 
PRESENT 
14 20 
TOTAL 
72 100 
 
 
Among the 72 male members recruited at the time of the study, 14 participants had 
metabolic syndrome prior to the initiation of antipsychotic medication. This is based 
on the NCEP ATP III criteria. This amounts to a prevalence rate of 20% among 
males. 
79 
 
Gender specific distribution according to the prevalence of metabolic syndrome 
in the patients at baseline 
 
Gender 
Number of participants with 
metabolic syndrome 
Percentage 
Male 14 50 
Female 14 50 
Total 28 100 
 
Comparison of the gender among the antipsychotic naive patients from the baseline 
population show equal distribution of males and females. 
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DISTRIBUTION OF THE VARIOUS INDIVIDUAL COMPONENTS OF THE 
METABOLIC SYNDROME AMONG THE PATIENTS WITH METABOLIC 
SYNDROME AT BASELINE 
 
Criterion 
Number 
of 
patients 
Percentage 
Total number 
of patients 
with 
metabolic 
syndrome at 
baseline 
 
WAIST 
CIRCUMFERENCE 
NORMAL 11 39.29 
28 
INCREASED 
 (males ≥ 90 cm, 
females  ≥ 80 
cm) 
17 60.71 
 
BLOOD PRESSURE 
NORMAL 
11 39.29 
28 INCREASED 
(≥130/≥85 mm 
Hg) 
17 60.71 
FASTING BLOOD 
SUGAR 
NORMAL 8 28.57 
28 
ELEVATED 
(≥100 mg/dl) 20 71.43 
TRIGLYCERIDES 
NORMAL 11 39.29 
28 ELEVATED 
(≥150 mg/dl) 17 60.71 
HDL 
CHOLESTEROL 
NORMAL 6 21.43 
28 
LOWERED 
(< 40 mg/dL  
males; < 50 
mg/dL females) 
 
22 78.57 
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Waist circumference in the participants with metabolic syndrome at baseline 
Out of the 28 patients who qualified for diagnosis of metabolic syndrome 17 
participants had increased waist circumference. This amounts to 61% of those with 
metabolic syndrome 
Analysis based on the gender wise distribution shows that 6 males had waist 
circumference above 90 cm and 11 females had waist circumference above 80 cm. 
This amounts to 39.29% and 21.43% respectively. 
 
 
0-<90cm(males); <80cm(females) 
1->90cm(males); >80cm(females) 
Distribution of the waist circumference among the participants with metabolic 
syndrome at baseline (n=28)
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Blood pressure in the participants with metabolic syndrome at baseline 
 
17 patients from the group of 28 patients who satisfied the diagnosis of metabolic 
syndrome had blood pressure values above 130/85 mmHg. This signifies that 60.71% 
of those with metabolic syndrome in this sample had hypertension. 
 
0- < 130mm Hg And  <85 mm Hg 
1- ≥130mm Hg OR≥85 mm Hg 
Distribution of the blood pressure among the participants with metabolic 
syndrome at baseline (n=28) 
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Fasting blood sugar levels in the participants with metabolic syndrome at 
baseline 
 
20 patients with metabolic syndrome in the antipsychotic naive status had fasting 
blood sugar values above100mg/dl. This means that in this sample of 28 patients with 
metabolic syndrome, 71% had elevated fasting blood sugars. 
 
 
.00- < 100 mg/dL 
               1.00- ≥140 mg/dL 
 
Distribution of the fasting blood sugar levels among the participants with 
metabolic syndrome at baseline (n=28) 
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Triglyceride levels in the participants with metabolic syndrome at baseline 
 
Among the 28 patients from the total of 148, who had been diagnosed with metabolic 
syndrome not induced by antipsychotic medications, 17 patients had elevated 
triglyceride levels above 150 mg/dl. 
So 60.71% of the patients with metabolic syndrome had hypertriglyceridaemia. 
 
0- <150 mg/dL 
1- ≥150 mg/dL 
Distribution of the triglyceride levels among the participants with 
metabolic syndrome at baseline (n=28) 
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HDL cholesterol levels in the participants with metabolic syndrome at baseline 
From the group of 28 patients identified to have metabolic syndrome at the onset of 
the study, 22 subjects had low levels of HDL cholesterol. This means that 79% of the 
patients who qualified for a diagnosis of metabolic syndrome using the NCEP ATP III 
definition had low levels of HDL cholesterol. 
Gender wise distribution shows that 12 out of the 22 patients with metabolic 
syndrome who had abnormal HDL cholesterol values belonged to the female gender. 
As depicted by the graph below, females contributed by 42.86% and males by 
35.71%. 
 
.00- > 40 mg/dL(males); >50 mg/dL (females) 
1.00- < 40 mg/dL(males); < 50 mg/dL (females) 
Distribution of the triglyceride levels among the participants with metabolic 
syndrome at baseline (n=28) 
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Prevalence of metabolic syndrome in the patients at the time of recruitment (IDF 
criteria) 
 
 
 
METABOLIC 
SYNDROME 
NUMBER OF 
PARTICIPANTS PERCENTAGE 
ABSENT 131 88 
PRESENT 17 12 
TOTAL 148 100 
 
 
Analysis of the participants recruited at the baseline of the study showed that based on 
the IDF criteria,   12% of the sample met the diagnosis of Metabolic syndrome, that is 
satisfying the waist circumference criteria and one out of 4 criteria. As shown in the 
table, 17 patients met these criteria. 
 
MetS-  Metabolic Syndrome absent 
MetS+ Metabolic Syndrome present 
 
Prevalence of the Metabolic Syndrome among the patients recruited (n=148) 
based onthe IDF criteria 
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SUB-THRESHOLD METABOLIC SYNDROME 
 
Prevalence based on satisfying at least two criteria of the metabolic syndrome 
according to the NCEP ATP III definition 
 
 
METABOLIC 
SYNDROME 
NUMBER OF 
PARTICIPANTS PERCENTAGE 
ABSENT 89 60 
PRESENT 59 40 
TOTAL 148 100 
 
The prevalence of metabolic syndrome in the sample was calculated based on the 
satisfaction of any two criteria. Based on the presence of any two criteria the overall 
prevalence of metabolic syndrome increased to   40%. This signifies an increase in the 
prevalence by 21% as opposed to when the standard definition requiring the 
satisfaction of 3 criteria (prevalence-19%) is used. 
 
MetS-  Metabolic Syndrome absent 
MetS+ Metabolic Syndrome present 
 
Prevalence based on satisfying at least two criteria of the metabolic syndrome 
(NCEP ATP III) 
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Prevalence based on satisfying at least one criteria of the metabolic syndrome 
according to the NCEP ATP III definition 
 
METABOLIC 
SYNDROME 
NUMBER OF 
PARTICIPANTS PERCENTAGE 
ABSENT 39 26 
PRESENT 109 74 
TOTAL 148 100 
 
When the prevalence of metabolic syndrome using a flexible definition requiring the 
need to satisfy any one of the five criteria was employed, the prevalence rose to 109 
participants out of the total of 148. This signifies a prevalence rate of   74%. This 
amount to more than 4 times the risk associated when the standard definition of 3 out 
of 5 criteria is used. 
 
MetS-  Metabolic Syndrome absent 
MetS+ Metabolic Syndrome present 
 
 Prevalence based on satisfying at least one criteria of the metabolic syndrome 
(NCEP ATP III) 
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Incidence of metabolic syndrome (NCEP ATP III) among the patients 
completing the study 
 
METABOLIC 
SYNDROME 
NUMBER OF 
PARTICIPANTS PERCENTAGE 
ABSENT 13 93 
PRESENT 1 7 
TOTAL 14 100 
 
Of the patients who were started on antipsychotic medications in the absence of 
metabolic syndrome, we were able to get complete data for 14 participants after 3 
months to assess the emergence of metabolic syndrome. Out of these 14 participants, 
one had developed metabolic syndrome. This gives an incidence of   7%. 
 
 
MetS-  Metabolic Syndrome absent 
MetS+ Metabolic Syndrome present 
 
 Incidence of Metabolic syndrome (NCEP ATP III criteria) at follow up (n=14) 
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SOCIO-DEMOGRAPHIC AND TYPE OF DIET DISTRIBUTION AMONG 
THE PATIENTS FOLLOWED UP (WITH COMPLETE DATA) 
Variable Number of patients Percentage 
Total number of 
patients at 
follow up with 
complete data 
 
GENDER 
MALE 
6 43 
14 
FEMALE 
8 57 
 
MARITAL 
STATUS 
SINGLE 
3 21 
14 
MARRIED 
11 79 
DIVORCED/ 
WIDOWED - - 
EDUCATION 
ILLITERATE 4 29 14 
LITERATE 10 71 
DIET 
VEGETARIAN 1 7 
14 NON-
VEGETARIAN 13 93 
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Distribution according to the Occupation of patients with complete data after 3 
months 
 
OCCUPATION NUMBER OF 
PARTICIPANTS PERCENTAGE 
ENGINEER 1 6.7 
HOTEL CHEF 1 6.7 
HOUSEWIFE 6 46.6 
LABORER 2 13.3 
LECTURER 1 6.7 
NIL 2 13.3 
UNEMPLOYED 1 6.7 
Total 14 100.0 
 
The 14 participants who were successfully followed up over 3 months had occupation 
status ranging from being unemployed to housewives to one lecturer. The majority 
comprised of housewives amounting to 47% of the followed up population. 
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Distribution of the antipsychotic medications prescribed among the participants 
followed up with complete data (n=14) 
 
MEDICATION 
DETAILS 
NUMBER OF 
PARTICIPANTS (n=14) 
PERCENTAGE 
(%) 
DOSAGE 
(mg) 
Risperidone only 9 64 4-8 
Olanzapine only# 4 29 20 
Risperidone 
+Aripiprazole* 1 7  
Aripiprazole only - - - 
Other antipsychotic 
medication - - - 
 
#- Out of the four patients who had been treated with Olanzapine three had been on 
20mg/day while one patient was on 7.5mg/day. 
* One participant who had been treated with oral Risperidone (8mg/day) developed 
intolerable extra-pyramidal side effects within two months and was being cross 
tapered to Aripiprazole at the time that the review blood investigations were done. At 
the time of blood collections the subject had been cumulatively on Risperidone 
(8mg/day) for two months, Risperidone (4mg/day) for two months and Aripiprazole 
(20mg/day) for one month. 
Out of the cohort of antipsychotic naive 14 patients with complete data, the single 
subject who had developed metabolic syndrome had been on Tab. Risperidone 
5mg/day. 
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Family history of Diabetes mellitus and metabolic syndrome (NCEP ATP III) 
 
 FAMILY HISTORY OF 
DIABETES MELLITUS Total 
ABSENT PRESENT 
METABOLIC SYNROME 
ABSENT 112 8 120 
 
PRESENT 
24 4 28 
Total  136 12 148 
 
 
The correlation between family history of Diabetes mellitus and metabolic syndrome 
(NCEP-ATP III criteria) among the antipsychotic naive patients at the time of 
recruitment was analysed using the 2x2 Chi square test. This gave Pearson Chi-
Square value of 1.769 with Fisher’s Exact Test p value of .241. This was not 
statistically significant. 
 
 
 
 
 
 
 
94 
 
Family history of Hypertension and metabolic syndrome (NCEP ATP III) 
 
 FAMILY HISTORY OF 
HYPERTENSION Total 
ABSENT PRESENT 
METABOLIC SYNROME 
ABSENT 114 6 120 
 
PRESENT 
24 4 28 
Total  138 10 148 
 
The correlation between family history of hypertension and metabolic syndrome 
(NCEP-ATP III criteria) among the antipsychotic naive patients at the time of 
recruitment was analysed using the 2x2 Chi square test. This gave Pearson Chi-
Square value of 3.107 with Fisher’s Exact Test p value of 0.095. This was not 
statistically significant. 
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Family history of Dyslipidemia and metabolic syndrome (NCEP ATP III) 
 
 
FAMILY HISTORY OF 
DYSLIPIDEMIA Total 
ABSENT PRESENT 
METABOLIC SYNROME 
ABSENT 115 5 120 
PRESENT 24 4 28 
Total  139 9 148 
 
The correlation between family history of dyslipidemia and metabolic syndrome 
(NCEP-ATP III criteria) among the antipsychotic naive patients at the time of 
recruitment was analysed using the 2x2 Chi square test. 
This gave Pearson Chi-Square value of 4.070 with Fisher’s Exact Test p value of 
0.066. This was not statistically significant. 
 
 
 
 
 
 
 
 
 
96 
 
Family history of Diabetes mellitus and Sub-threshold metabolic syndrome 
(NCEP ATP III) 
 
 
FAMILY HISTORY OF 
DIABETES MELLITUS Total 
ABSENT PRESENT 
SUB-THRESHOLD 
METABOLIC 
SYNROME 
(at least 2 criteria of 
NCEP ATP III) 
ABSENT 83 6 89 
PRESENT 53 6 59 
Total  136 12 148 
 
 
The correlation between family history of Diabetes mellitus and sub-threshold 
metabolic syndrome (satisfying at least 2 out of the 5 NCEP-ATP III criteria) among 
the antipsychotic naive patients at the time of recruitment was analysed using the 2x2 
Chi square test. This gave Pearson Chi-Square value of 0.560 with Fisher’s Exact Test 
p value of .543. This was not statistically significant. 
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Family history of Hypertension and Sub-threshold metabolic syndrome (NCEP 
ATP III) 
 
 
FAMILY HISTORY OF 
HYPERTENSION Total 
ABSENT PRESENT 
SUB-THRESHOLD 
METABOLIC 
SYNROME 
(at least 2 criteria of 
NCEP ATP III) 
ABSENT 85 4 89 
PRESENT 53 6 59 
Total  138 10 148 
 
The correlation between family history of hypertension and sub-threshold metabolic 
syndrome (satisfying at least 2 out of the 5 NCEP-ATP III criteria) among the 
antipsychotic naive patients at the time of recruitment was analysed using the 2x2 Chi 
square test. This gave Pearson Chi-Square value of 1.814 with Fisher’s Exact Test p 
value of 0.198. This was not statistically significant. 
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Family history of Dyslipidemia and Sub-threshold metabolic syndrome (NCEP 
ATP III) 
 
 
FAMILY HISTORY OF 
DYSLIPIDEMIA Total 
ABSENT PRESENT 
SUB-THRESHOLD 
METABOLIC 
SYNROME 
(at least 2 criteria of 
NCEP ATP III) 
ABSENT 84 5 89 
PRESENT 55 4 59 
Total  139 9 148 
 
The correlation between family history of dyslipidemia and sub-threshold metabolic 
syndrome (satisfying at least 2 out of the 5 NCEP-ATP III criteria) among the 
antipsychotic naive patients at the time of recruitment was analysed using the 2x2 Chi 
square test. 
This gave Pearson Chi-Square value of 0.084 with Fisher’s Exact Test p value of 
1.00. This was not statistically significant. 
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Family history of Diabetes mellitus and Sub-threshold metabolic syndrome 
(NCEP ATP III) 
 
 
FAMILY HISTORY OF 
DIABETES MELLITUS Total 
ABSENT PRESENT 
SUB-THRESHOLD 
METABOLIC 
SYNROME 
(at least 1 criterion of 
NCEP ATP III) 
ABSENT 35 4 39 
PRESENT 101 8 109 
Total  136 12 148 
 
 
The correlation between family history of Diabetes mellitus and metabolic syndrome 
(NCEP-ATP III criteria) among the antipsychotic naive patients at the time of 
recruitment was analysed using the 2x2 Chi square test. This gave Pearson Chi-
Square value of 0.328 with Fisher’s Exact Test p value of 0.516. This was not 
statistically significant. 
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Family history of Hypertension and Sub-threshold metabolic syndrome (NCEP 
ATP III) 
 
 
FAMILY HISTORY OF 
HYPERTENSION Total 
ABSENT PRESENT 
SUB-THRESHOLD 
METABOLIC 
SYNROME 
(at least 1 criterion of 
NCEP ATP III) 
ABSENT 37 2 39 
PRESENT 101 8 109 
Total  138 10 148 
 
 
The correlation between family history of hypertension and metabolic syndrome 
(NCEP-ATP III criteria) among the antipsychotic naive patients at the time of 
recruitment was analysed using the 2x2 Chi square test. This gave Pearson Chi-
Square value of 0.223 with Fisher’s Exact Test p value of 1.00. This was not 
statistically significant. 
 
 
 
 
 
 
 
101 
 
Family history of Dyslipidemia and Sub-threshold metabolic syndrome (NCEP 
ATP III) 
 
 
FAMILY HISTORY OF 
DYSLIPIDEMIA Total 
ABSENT PRESENT 
SUB-THRESHOLD 
METABOLIC 
SYNROME 
(at least 1 criterion of 
NCEP ATP III) 
ABSENT 35 4 39 
PRESENT 104 5 109 
Total  139 9 148 
 
 
The correlation between family history of dyslipidemia and metabolic syndrome 
(NCEP-ATP III criteria) among the antipsychotic naive patients at the time of 
recruitment was analysed using the 2x2 Chi square test. 
This gave Pearson Chi-Square value of 1.616 with Fisher’s Exact Test p value of 
0.244. This was not statistically significant. 
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INCIDENCE OF THE INDIVIDUAL COMPONENTS OF THE METABOLIC 
SYNDROME AFTER ANTIPSYCHOTIC USE 
 
Incidence of increase in waist circumference 
 
WAIST AT FOLLOW UP 
INCREASED NORMAL 
 
WAIST AT BASELINE 
INCREASED 3 3 
NORMAL 11 11 
Total  14 14 
 
 
Among the 14 participants at follow up who had complete data, 3 had increase in their 
waist circumference above the norms. All three of them were female. The very same 
participants also had increased waist circumference at baseline. They had been 
recruited as they did not satisfy the diagnosis of metabolic syndrome at baseline 
according to the NCEP ATP III criteria. Since the very same participants continued to 
have increased waist circumference the incidence of increase in waist circumference 
in this population was zero. 
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Incidence of hypertension 
 
 
BLOOD PRESSURE AT FOLLOW 
UP 
INCREASED 
(≥130/≥85 mm Hg) 
NORMAL 
BLOOD 
PRESSURE 
AT BASELINE 
INCREASED 
(≥130 OR ≥85 mm 
Hg) 
0 0 
NORMAL 14 14 
Total  14 14 
 
Among the 14 participants at follow up who had complete data, none had increase in 
their blood pressure above the norms.  None of them had elevated blood pressure 
readings at the baseline. So the incidence of increase in blood pressure in this sample 
was zero. 
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Incidence of increase in fasting blood sugar levels  
 
 
FASTING BLOOD SUGAR AT 
FOLLOW UP 
INCREASED 
(≥100 mg/dl) 
NORMAL 
FASTING BLOOD 
SUGAR 
AT BASELINE 
INCREASED 
(≥100 mg/dl) 
1 1 
NORMAL 13 13 
Total  14 14 
 
 
Among the 14 participants at follow up who had complete data, one subject had 
increase in the fasting blood sugar values above the norm. This was a male. He had 
fasting blood sugar level within normal limits at baseline.  There was one female 
participant who had elevated blood sugar level at the time of the baseline but did not 
satisfy the diagnosis of metabolic syndrome at baseline according to the NCEP ATP 
III criteria. On follow up her fasting blood sugar level had normalised. With this 
information, the incidence of increase in fasting blood sugar in this sample could be 
considered to be 7%. 
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Incidence of increase in triglyceride levels  
 
 
TRIGLYCERIDE LEVELS AT 
FOLLOW UP 
INCREASED 
(≥150 mg/dl) 
NORMAL 
TRIGLYCERIDE 
LEVELS 
AT BASELINE 
INCREASED 
(≥150 mg/dl) 
3 2 
NORMAL 11 12 
Total  14 14 
 
Among the 14 participants at follow up who had complete data, three subjects had 
triglyceride blood levels above the norm at the base line but did not satisfy the 
diagnosis of metabolic syndrome at baseline according to the NCEP ATP III criteria.  
Two out of these three individuals had normal blood levels of triglycerides at the time 
of follow up. One participant continued to have elevated triglyceride levels. Another 
subject who had normal triglyceride levels at the baseline had developed new onset 
hypertriglyceridemia by the follow up period. With this information, the incidence of 
increase in fasting blood sugar in this sample could be considered to be 7%. 
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Incidence of decrease in HDL cholesterol levels 
 
 
HDL CHOLESTEROL LEVELS AT 
FOLLOW UP 
DECREASED 
(<40 mg/dl in males; 
<50 mg/dL in females) 
NORMAL 
HDL 
CHOLESTEROL 
AT BASELINE 
DECREASED 
(<40 mg/dl in 
males; 
<50 mg/dL in 
females) 
10 5 
NORMAL 4 9 
Total  14 14 
 
Among the 14 participants at follow up who had complete data, ten subjects had 
lowered HDL cholesterol blood values below the norm at the base line but did not 
satisfy the diagnosis of metabolic syndrome at baseline according to the NCEP ATP 
III criteria. These included five males and five females. Out of them five continued to 
have lowered HDL cholesterol levels at follow up. At the follow up the group that 
continued to have low levels of HDL cholesterol comprised of four males and one 
female. As no participants developed new onset abnormality in HDL cholesterol 
levels, the incidence of decrease in HDL cholesterol levels in this sample was zero. 
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DISCUSSION 
 
At the start of the study we had screened 314 patients. 31 patients exercised their right 
not to give informed consent. 
Of the remaining 283, 39 patients who had given informed consent failed to follow up 
in the outpatient department after the index visit. The reasons for this attrition based 
on the enquiry over the phone included improvement in symptoms, complete 
resolution of symptoms and promises of following up which were not met. Complete 
information could not be compiled as a number of contacts did not respond to the 
telephone enquiry.  
Another 36 patients out of the 244 patients who gave consent, did not do the blood 
investigations at all.  
Of the remaining 208, 60 patients could not be included due to our adherence to the 
requirement of doing the blood investigations within one week of the start of 
antipsychotic medications to cancel the effect of the medication on the metabolic 
profile. Blood investigations were done after the first week by 44 of the participants 
(being late by one day to two weeks)  
16 participants had done the blood tests incompletely (12 had only done fasting blood 
sugars while 4 had only the lipid parameters checked). Possible reasons include two 
separate slips for each of these components leading to missing of one; tests being 
missed by the primary clinician.  
Our adoption and strict adherence to, a one week criteria, seems to have contributed to 
a number of patients not getting recruited into the study. As most of the patients 
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attend psychiatric services in non-fasting state, checking of blood parameters at the 
index visit does not seem feasible. Other options could include provisions of 
providing added incentives for following up the very next day for the blood 
investigation or making house visits within the one week period. The cost 
effectiveness of such strategies will need evaluation. One of the ethical issues that has 
been highlighted in literature is the prevalence of “cold calling” in follow up 
studies(131). Cold calling refers to visiting participants at home without prior 
agreement. Since the purpose of home visits is for obtaining blood samples in fasting 
state, home visits will have to be done with prior agreement. The issues discussed 
above highlight the complexities involved in conducting a prospective cohort study in 
a clinical setting of psychiatric patients.  One of the examples is the landmark 
BALANCE (Bipolar Affective disorder: Lithium/ANtiConvulsant Evaluation)trial 
where in the protocol was changed three times due to relevant clinical issues(132). 
This would recommend a balance between the adoption of more flexible measures to 
ensure good sample collection and rigid criteria to ensure qualitative standards. 
Out of the total 148 subjects recruited for this study 49% were male and 52% were 
female. According to the population demographics data published in the Indian 
Census 2011, the national sex ratio is 940 females per 1000 males(133). The state of 
Tamil Nadu where this study was done had a higher sex ratio of 996 females per 1000 
males(133). The overall trend since 2001 has been an increase in this ratio. Hence the 
gender distribution of the participants in our study can be considered to be reflective 
of the local general population. 
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The mean age of the patients in our study was 36 years, though the participant’s age 
ranged from 18 years to 65 years. The majority of patients recruited in this study were 
suffering from psychotic illnesses, predominantly with schizophrenia. It has been well 
established that Schizophrenia strikes in young adults(134). This could explain the 
relatively younger mean age of our sample. About 66% of the subjects in our study 
were married, while 30% were single and the remaining 4% belonging to widowed 
status. According to the Indian Census 2011,  in Tamil Nadu about 50.5% of the 
population were married with 41.9% single and remaining 7.6%  in either widowed, 
separated or divorced status(133). The mean age at effective marriage in Tamil Nadu 
as of 2011 was 22.4 years(133). Given that our sample comprised of relatively 
younger mean age, this could explain the higher proportion of married participants in 
our study. 
In our study sample 80% of the participants were literate. This correlates with the 
Indian Census 2011 figures of literacy rate of 80.3% in Tamil Nadu(133). Our sample 
is hence representative of the local population on this aspect as well. 
Prevalence of the metabolic syndrome in antipsychotic naive mentally ill 
population 
 Out of the 148 patients recruited, abnormal HDL cholesterol levels were present in 
83 subjects (44%) followed by raised triglycerides 36(24%), raised blood pressure 30 
(20%), increased waist circumference 24 (16%) and impaired fasting glucose 17 
(11%).   
Using the criteria given by the criteria given by the NCEP ATPIII criteria 28 
participants from the 147 participants recruited fulfilled the diagnosis of metabolic 
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syndrome.  This is a prevalence rate of 19%. Most of the earlier Indian studies report 
prevalence rates varying from 18.3% (39) to as high as 33.5%(87). There are however 
differences in the diagnostic guidelines employed by these studies.  
The prevalence of metabolic syndrome is lower in our study sample when compared 
with some previous studies (38). This can be attributed to the younger mean age as it 
has been shown that the prevalence of metabolic syndrome increases with increasing 
age.  
Another factor could be the demographic and socio-economic profile of the patients 
using this facility. Most of the patients recruited in this study belong to the lower 
socio-economic strata, while studies in India have shown positive correlation between 
metabolic syndrome and middle to high socio-economic status(87). Previous Indian 
study samples merged data of truly antipsychotic naive patients with those who had 
been off the antipsychotic medication for a specified duration of time(54,103). In our 
study we strictly adhered to the inclusion of only those patients who had never been 
exposed to antipsychotic medication. Therefore the data collected from this sample of 
patients would represent the incidence of deranged metabolic status in truly 
antipsychotic naive population where in carry over effects of previous antipsychotic 
medication use is absent. 
Another difficulty in comparison with  other Indian research, is that many studies did 
not recruit antipsychotic naive participants(98,102,135). Previous Indian research 
varies in the duration for which participants were on antipsychotic medications, 
ranging from short durations of 6 weeks (57) and 8 weeks (99) to one year 
duration(95) 
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Using the IDF criteria, the prevalence rate in this study is 12%. Previous Indian 
studies report prevalence rates using the IDF criteria from as low as 10.86% (101) to 
as high as 18.2% (104) in patients with schizophrenia. Hence the prevalence rate in 
this study using the IDF criteria is comparable to findings from other parts of India. 
The comparative lower prevalence rate when using the IDF criteria could be attributed 
to its more restrictive pattern of diagnosis which requires the presence of central 
obesity as a prerequisite. 
The gender specific prevalence of metabolic syndrome in our sample, calculated 
according to the NCEP ATP III guidelines gives a comparable prevalence rates 
among the genders (female 16% and male 17%).This is in keeping with earlier 
international studies which have shown an equal prevalence of metabolic syndrome in 
males and females(136). On the other hand  some Indian studies have shown higher 
prevalence among females(38,86).  
Substance use and the metabolic syndrome 
About 18% of the patients in our study had concomitant use of tobacco. Though the 
earlier concept was that tobacco has protective effects on central obesity(56,96),  it 
has been established that tobacco has positive correlation with metabolic 
syndrome(137–139).  Analysis of association between tobacco use and the prevalence 
of metabolic syndrome using Chi square comparison did not yield any statistically 
significant results. 
 Of the total 148 patients 14% also used alcohol, though not amounting to dependence 
pattern. Heavy alcohol use has been associated with metabolic syndrome(140).  
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Statistical analysis did not however reveal any significant association between alcohol 
use and the prevalence of metabolic syndrome in the population recruited.  
With the current data from this study we cannot demonstrate a relationship between 
substance use and metabolic syndrome.  
Family history as a risk factor 
In our study sample family history of dyslipidemia, hypertension and diabetes 
mellitus was present in 6%, 7% and 8% respectively. Analysis of the association 
between these family histories and the prevalent metabolic syndrome in the recruited 
population did not show any statistically significant results.  
We also analysed the correlation between family history and presence of sub-
threshold metabolic syndrome, however statistically significant association was not 
found.  Literature review also showed limited information for the correlation between 
family history and metabolic syndrome except for some studies on the positive 
correlation with family history of cardiovascular disease(141) and diabetes 
mellitus(142). Though a positive correlation seems plausible theoretically, the data 
from the current study does not support this. 
Diet and the metabolic syndrome 
Based on the diet patterns, 87 % of the patients in our study were on non-vegetarian 
diet.  Our analysis did not yield any statistically significant associations between the 
type of diet and metabolic syndrome. There is inconclusive evidence in the literature 
about the protective effects of vegetarian diet on metabolic syndrome(143,144). This 
would also be governed by genetic variations in different ethnicities. 
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Prevalence of at least two and at least one component of metabolic syndrome 
In our baseline sample 40% participants satisfied at least two components of the 
metabolic syndrome. In comparison about 74% subjects satisfied at least one 
component of the metabolic syndrome criteria as defined by NCEP ATP III. Recently, 
pooled data from three Indian studies on patients with schizophrenia showed that 
when antipsychotic naive patients were checked for the sub-threshold metabolic 
syndrome defined by  criteria of satisfying either at least two or at least one out of the 
5 components, the prevalence rates were 23.3%  and 40.9% respectively(96). 
The prevalence of the individual components of the metabolic syndrome in 
antipsychotic naive patients in our study is much higher. This is a finding that requires 
further study.  
This also highlights the need for further research on antipsychotic naive patients to 
identify sub-threshold metabolic syndrome and the risk factors that can be targeted in 
prevention strategies against progression to full blown metabolic syndrome. 
Distribution of individual components of metabolic syndrome 
Among the 28 antipsychotic naive patients who were diagnosed to have metabolic 
syndrome at the outset using the NCEP ATP III criteria, 78.57% had abnormal HDL 
cholesterol levels, followed by 71.43% with elevated fasting blood sugar levels and 
60.72% with increased waist circumferences. 60.71% participants had both 
hypertriglyceridemia and hypertension. So this means that maximum number of 
patients had abnormal HDL cholesterol levels followed by waist circumference & 
elevated fasting blood sugar levels. This is different from one study which found 
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blood pressure, HDL cholesterol and triglycerides to be the most common 
components contributing to the metabolic syndrome(86).  
As the number of patients with complete data on follow up was small, factor analysis 
between the individual components of the metabolic syndrome and antipsychotic 
medication use could not be done.  
One component which has been found to be among the most common contributors to 
metabolic syndrome in Indian studies has been increased waist 
circumference(38,83,84). This difference may be due to the ethnic and genetic 
propensity for Indians to develop central obesity. This would suggest that diagnostic 
criteria using waist circumference as one of the major components might be of more 
relevance to the Indian population. This trend is not seen in this study. 
Incidence of metabolic syndrome 
Out of the 147 patients recruited for this study only 14 patients could be followed up 
after 3 months for assessment of metabolic syndrome. This accounts for 10% of the 
sample recruited. Of this 10%, participants belonging to the female gender comprised 
of 47%. The rate of literacy did not markedly differ between the baseline population 
and the follow up population.  Since the attrition rate was as large as 90%, the 
incidence rates and the risk factor variables could not be statistically analysed any 
further.   
89 patients did not come for follow up visits to the outpatient department. Attempts 
were made to ensure adherence with therapy by calling up individual patient on their 
mobile phones. A number of participants responded to the phone calls with promises 
of following up in the outpatient clinics which did not materialize. Reasons given over 
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the phone for not coming for the review appointments included improvement in 
symptoms and in some cases complete resolution of symptoms. Complete information 
could not be compiled as many contacts did not respond to the telephone enquiry. 
8 patients attended the outpatient department, but did not come in a fasting state for 
the blood measurements, and therefore, could not provide the required data. 
Measuring the blood parameters at the patient’s local medical laboratory was 
considered but decided against, due to the lack of standardization of quality of 
analysis. 
The incidence of metabolic syndrome using the NCEP ATP III criteria among the 
patients followed up is 7%. This corresponds with incidence rate of 11% reported by 
another recent study from northern part of India (103). In this small sample among the 
individual components of the metabolic syndrome only parameters with new onset 
abnormalities were in fasting blood sugar and triglyceride levels. This increase was by 
one case in each parameter. Inferences cannot be made on this finding.  Due the small 
sample of the follow up the correlation between the defined variables and the 
incidence of metabolic syndrome could not be analysed. As none of the followed up 
participants had increased waist circumference, incidence was zero using the IDF 
criteria. 
Antipsychotic medication and the incidence of metabolic syndrome 
In our study sample, majority of the patients had been on the atypical antipsychotic 
medication Risperidone, followed by Olanzapine. According to international studies, 
Risperidone is associated with relatively lesser propensity to develop metabolic 
syndrome in comparison to Olanzapine(61,62,66). Though these studies were done 
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predominantly in American and European populations, recent literature review has 
shown that the risks associated with use of atypical antipsychotic medications are 
comparable in East Asian and other populations(146).  
In this study the single individual who developed metabolic syndrome among the 14 
participants (with complete data) was on Risperidone. The lack of adequate sample 
size impedes any statistical interpretation of these findings. However clinically it 
would be advisable for clinicians to consider and guard against metabolic syndrome 
even when antipsychotic medications of lesser risk profile like Risperidone are 
prescribed. 
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Strengths of the study 
1. This study examined an area that is of clinical significance and for which there 
is sparse national or regional information. 
2. In this study consecutive patients attending the tertiary care psychiatric 
services in Southern India were recruited. This limited selection bias. 
3. The sample included only antipsychotic naive patients which are in contrast to 
numerous previous studies which have merged data from purely antipsychotic 
naive and those off antipsychotic medications for stipulated periods of time, 
and therefore measured true incidence. 
4. Data regarding risk factors like family history had been compiled which has 
been missed out in previous studies. 
Limitations of the study 
1. The baseline sample size could not be reached. 
2. The dropout rate was very high. 
3. Adherence to a strict protocol resulted in further attrition of data. 
4. Although most of the results  replicate findings from previous studies, the 
results are marred by  lack of statistical significance 
5. Due to the large loss to follow up, all planned statistical calculations could not 
be done.  
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Clinical Implications 
This study has found that the prevalence of metabolic syndrome in patients with 
mental illness attending the services of this tertiary care psychiatric centre in South 
India is high even before the start of antipsychotic therapy. The presence of sub 
threshold metabolic syndrome is also very high. 
This study also highlights the high rate of drop out among patients with psychiatric 
illness, in spite of active measures to ensure good adherence to therapy. 
Clinicians need to be aware of the implications regarding the prescription of 
psychiatric medications and the preventive measures that need to be adopted against 
the development of metabolic syndrome. 
Baseline recording of anthropometric data and the laboratory parameters is essential 
before starting antipsychotic medications. This would enable the identification of 
vulnerable patients and inform clinical practice on the choice of antipsychotic 
medication. 
This study also shows that clinicians need to remain vigilant while prescribing 
antipsychotic medications with relatively lesser risk of metabolic syndrome. 
In addition this study also highlights the importance of having monitoring schedules 
in place to ensure that the development of any new features of metabolic syndrome 
among patients on antipsychotic medications is not missed. This should comprise of 
regular physical measurements and laboratory investigations. 
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Future directions 
Prospective studies using a cohort design of antipsychotic naive patients with a 
control group should provide accurate data on the incidence of metabolic syndrome. 
The choice of a suitable control group where antipsychotic medication will not be 
administered raises several ethical issues and requires careful planning. 
 Studies with large sample sizes and good follow up rates will inform clinical practice. 
High dropout rates are a clinical reality. Hence, improving follow up rates and data 
collection is a challenge. Strategies possible include offering incentives for remaining 
in follow up, using local laboratory facilities for tests, and home visits with consent 
for this to be included at the start of the study. These raise ethical, financial, and 
quality control issues during the planning.  
This study has demonstrated that a large proportion of patients with mental illness 
already have deranged metabolic functions, with a significant subset qualifying for the 
diagnosis of metabolic syndrome even prior to the institution of antipsychotic 
medication therapy. This highlights the need for further studies to explore the 
relationship between metabolic syndrome and mental illness. Further research needs 
to focus on the factors contributing to this increased prevalence. 
Nearly 75% of the sample had at least one deranged metabolic parameter before 
treatment. This underlines the need for further exploration of sub-threshold metabolic 
syndrome, and the appropriateness of the cut offs to qualify for a diagnosis of the full 
syndrome.  
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Another finding from this study is the high rates of drop out to tertiary psychiatric 
care service. This opens up another avenue for research into factors affecting 
adherence with mental health care.  
Finally this study has replicated similar incidence rates for antipsychotic drug 
emergent metabolic syndrome as in other Indian studies. Indian psychiatrists must 
enforce screening, primary prevention, and early detection and treatment of this 
syndrome. 
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SUMMARY 
Introduction 
 
Metabolic syndrome constitutes a constellation of risk factors which predispose 
individuals toward the development of diabetes mellitus and coronary artery disease.  
Studies have demonstrated association between metabolic syndrome and mentally ill 
patients. With the current shift in psychopharmacological prescription patterns and the 
increased use of second generation antipsychotics, the significance of metabolic 
syndrome in psychiatric populations has increased. Other contributing factors in the 
mentally ill patients towards development of metabolic syndrome are sedentary life 
style and diet. 
Extensive literature review revealed a dearth of data on both the prevalence of 
metabolic syndrome and the incidence of metabolic syndrome among Indian 
populations with mental illness. 
Methodology 
A prospective cohort  study was conducted where the prevalence of metabolic 
syndrome in antipsychotic naive patients was measured at the time of recruitment. 
Those who did not fulfil the criteria for metabolic syndrome and required 
antipsychotic medications were followed up over a period of 3 months and reassessed 
for the incidence of metabolic syndrome. Participants fulfilling the inclusion and 
exclusion criteria were recruited from both outpatient and inpatient facilities in the 
department of Psychiatry, Christian Medical College, Vellore. This was done after 
obtaining written informed consent. Socio-demographic, anthropometric, blood 
pressure and blood parameters (HDL cholesterol, triglycerides, and fasting blood 
sugars) were recorded in addition to making note of other risk factors such as family 
history. 
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Results 
The analysis of the baseline characteristics was done using 148 participants. The 
prevalence of metabolic syndrome in antipsychotic naive patients with mental illness 
was 19% using the NCEP ATP III definition while it was 12% when using the IDF 
criteria. The prevalence of sub threshold metabolic syndrome was 40% when only 2 
criteria and 74% when any one of the NCEP ATP III criteria were fulfilled. 
Full data was available for 14 participants three months later. In this sub group the 
incidence rate for metabolic syndrome was 7% using the NCEP ATP III definition. 
Conclusion 
The prevalence of metabolic syndrome in drug naïve patients was found to be 
comparable to other Indian studies. The prevalence of sub-threshold metabolic 
syndrome was much higher than previously reported. 
There was a high dropout rate. 
The incidence rate of metabolic syndrome was comparable to one earlier Indian study. 
There is need for further studies to identify the clear incidence and risk factors of 
metabolic syndrome with antipsychotic use.  
This study also highlights the need for clinicians to be thoughtful about choosing 
antipsychotic medications, to document relevant clinical parameters before starting 
therapy, to be aware of the risks of precipitating metabolic syndrome in vulnerable 
populations and to adopt necessary strategies to prevent the emergence of this 
syndrome. 
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APPENDIX 1 
Participant Information Sheet 
“Incidence of metabolic syndrome in patients receiving antipsychotic 
medication” 
 
My name is Dr. Akhil Abhijnhan and I am doing a research on a condition called 
metabolic syndrome. The research will be done in Department of Psychiatry, CMC, 
Vellore. 
Medications can cause various side effects and antipsychotic drugs which you are 
receiving may result weight gain, rise in blood sugar, blood pressure and cholesterol.  
I am aiming to find out these by checking your waist circumference and testing your 
blood. I would like to request you to donate 10 ml (2 teaspoonfuls) of blood during 
my study. Your blood and waist circumference will be checked twice: once at the 
time that you are enrolled into this study and a second time after 3 months.  I will also 
be collecting information regarding your illness from the case record kept in the 
hospital. 
The blood will be taken using sterile (clean) methods by a trained technician. Your 
information will not be revealed to anyone and all information about you and your 
treatment will be kept confidential. The blood tests will be done free of cost and the 
bus fare for coming to hospital for doing blood tests will be reimbursed for local 
patients. This study is not likely to be of any direct benefit to you. 
You have every right to refuse to take part in this study. Your treatment will not be 
affected by this. 
If you have any doubts you can contact me at 04162284520, department of 
Psychiatry, CMC, Vellore. Email: akhil.abith@gmail.com. 
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APPENDIX 2 
Consent Form 
“Incidence of metabolic syndrome in patients receiving antipsychotic 
medication” 
    
I..........................................................residing in.................................................. 
....................................... give consent  to take part in a study that looks at presence of 
raised blood sugars, cholesterol, blood pressure and weight in patients receiving 
antipsychotic medication. The research has been explained to me in the language 
known to me. I was given the chance to ask questions about the study. I have received 
an information sheet as well in my regional language. 
    My treatment will be the same whether I take part in the study or not. There is no 
direct benefit to me because of this study. I will not receive any money or gift for 
taking part in the study other than the travel expenses. My personal details will not be 
disclosed to anyone .I have no objection for the study results being published in a 
scientific journal .I can withdraw from the study at any point of this research. 
 Signature of the participant/Thumb impression:                                 Date 
Signature of the researcher:                                                                Date 
Relative’s Consent Form 
I.......................................................... being the............................................ of 
...................................................... hereby confirm that I have been explained about the 
study titled “Incidence of metabolic syndrome in patients receiving antipsychotic 
medication”. I have been explained in detail about the purpose and procedures 
involved in this study. 
..........................................................  hereby give consent on behalf of the patient for 
this study. 
Signature of the relative/Thumb impression:                                       Date 
Relation to the patient: 
 
Signature of the researcher:                                                                Date 
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